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The clinical development of prophylactic HIV-1/AIDS vaccines is confounded by numerous scientiﬁc
challenges and these in turn result in challenges to regulators reviewing clinical trial applications (CTAs).
The search for an HIV-1/AIDS vaccine will only succeed through the conduct of well-designed, well-
conducted and well-controlled human efﬁcacy studies. This review summarizes relevant context in
which HIV vaccines are being investigated and the six completed efﬁcacy trials of various candidate
vaccines and regimens, as well as the lessons learned from them relevant to regulatory evaluation. A
companion review focuses on the scientiﬁc challenges regulators face and summarizes some current
candidates in development. The lessons learned from the completed efﬁcacy trials will enable the
development of better designed, potentially more efﬁcient efﬁcacy trials in future. This summary, sup-
ported by the World Health Organization (WHO), is unique in that it is meant to aid regulators in un-
derstanding the valuable lessons gained from experience in the ﬁeld to date.
© 2016 The Authors. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Contents
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R.L. Sheets et al. / Biologicals 44 (2016) 73e89741. Introduction e scope and purpose of review The primary route of transmission of HIV remains heterosexual
transmission. However, intravenous drug use (IDU or PWID eProphylactic Human Immunodeﬁciency Virus Type 11 (HIV)
vaccine clinical trials, including efﬁcacy trials, are being conducted
in countries worldwide. Many of the countries hardest hit by the
HIV/AIDS (Acquired Immunodeﬁciency Syndrome) epidemic are in
sub-Saharan Africa or Asia and most of those are in low- and
middle-income countries. The World Health Organization (WHO)
has the responsibility to aid countries in enhancing regulatory ca-
pacity and undertook this review to frame scientiﬁc issues relevant
to the development of HIV/AIDS vaccines, in the context of regu-
latory review and evaluation. The purpose of this is to facilitate the
development process and sound regulation of HIV/AIDS clinical
trials, as well as to provide technical support to regulators.
Currently, the development of experimental preventive HIV/AIDS
vaccines includes a wide variety of innovative and complex ap-
proaches without precedent in other licensed vaccines. Lessons
learned from completed clinical trials using such new approaches,
e.g., vectored vaccines or heterologous prime-boost immunization,
can be informative to regulators as they face review of future
clinical trial applications (CTAs) as the search for a safe, efﬁcacious,
globally useful HIV/AIDS vaccine continues. WHO has been facili-
tating the research and development of HIV/AIDS vaccines and
providing support to strengthen the technical capacity of regulators
in assessing CTAs for HIV/AIDS vaccines. This review is intended to
summarize some of those lessons learned relevant to regulators
and regulatory evaluation.
In response to requests to WHO from regulators, vaccine de-
velopers, and manufacturers on HIV/AIDS vaccines, a review of six
completed clinical efﬁcacy trials conducted with HIV/AIDS vaccine
candidates was undertaken by WHO in order to provide a
comprehensive overview of the main challenges and lessons
learned during the preparation, conduct, monitoring and data
interpretation of these trials. Key outcomes of the review are
summarized in this article with the aim of making a compilation of
the knowledge about HIV/AIDS vaccine development available to
regulators, manufacturers, academia, funding agencies and other
relevant stakeholders engaged in various aspects of HIV/AIDS vac-
cine development and regulatory evaluation. A companion review
summarizes the most advanced candidate vaccines likely to move
forward to future efﬁcacy trials and the scientiﬁc challenges that
remain in the ﬁeld of HIV/AIDS vaccines, which present regulatory
challenges.2. HIV epidemiology
According to the UNAIDS 2014 Gap Report [1] 39 million people
are living with HIV today. Of these, 3.2 million are children under
the age of 15 and 18.5 million of those are women or girls. The
majority of these cases are in Sub-Saharan Africa, where the esti-
mates are 24.7 million. There are an additional 4.8 million cases in
South and South-East Asia.
Due to the way that statistics are gathered and calculated, ad-
olescents aged 15 years of age and older are included in the esti-
mates for adult statistics. However, adolescence is a period of
tremendous increased risk for acquiring HIV infection as sexual
activity is initiated. Thus, this age group is undeniably the target
population for a successful vaccine; however, there are challenges
to conducting studies in this vulnerable population.1 Throughout this review, the terms HIV or HIV/AIDS will be used and refer to
HIV-1. To our knowledge, few, if any efforts are ongoing in clinical development of
HIV-2 vaccines, so this review is strictly conﬁned to HIV-1.peoplewho inject drugs), mother to child transmission (MTCT), and
menwho have sex withmen (MSM) remain important contributors
to the transmission rates around the world.
Although in many countries, transmission rates are slowing, the
existing prevention modalities have not completely controlled the
epidemic. Improvements in prevention modalities, including
treatment of infected individuals to reduce transmission rates to
uninfected partners, are increasingly prevalent and more widely in
use. Their impact is being seen in the reduction in transmission
rates; however, these improvements have not eliminated the
epidemic in any one country. Thus, the need for a vaccine that can
prevent acquisition of HIV infection is still undeniable. No thought
can be given to eliminating the disease of AIDS without a prophy-
lactic vaccination programme.
3. Need for a vaccine in context of other prevention strategies
Considerable progress [2] has been made in the past decade on
prevention modalities; male circumcision, treatment of the HIV-
infected partner to prevent infection in the sero-discordant part-
ner, post-exposure prophylaxis (PEP), pre-exposure prophylaxis
(PrEP), and microbicides. These more recent prevention strategies
add to the existing strategies of blood supply safety, condom use,
access to sterile injection equipment, delay to initiation of sexual
activity or abstinence, monogamy between known uninfected
partners, voluntary testing and counseling, and knowledge,
including knowing one's current infection status and how to pro-
tect oneself.
It has been questioned whether an HIV/AIDS vaccine is even
feasible. Given the ever increasing number of successful prevention
strategies, some question the effort towards vaccine development.
While it is true that in some countries, declines in HIV incidence
have thankfully been achieved with existing and new prevention
strategies; in other countries, the epidemic is still increasing. In no
one country has the epidemic been controlled or eliminated. Suc-
cessful vaccines have resulted in the control and in some cases
elimination of many infectious diseases, including diphtheria,
measles and polio (among many others). The smallpox vaccine
permitted eradication on a global scale of that disease. Thus, it is
likely that only with the development of a successful HIV/AIDS
vaccine can the control of this epidemic be conceivable. Despite
numerous challenges, discussed in the companion review, the
effort to develop an HIV/AIDS vaccine should not be abandoned.
Given that individuals, once infected, remain infected for the rest of
their lives and can potentially transmit infection to others
throughout this time (although effective anti-retroviral treatment
that controls viral load leads to successful interruption of trans-
mission as long as the treated individual remains adherent and
does not develop drug-resistance resulting in loss of viral load
control), disease control in a public health sense can only be ach-
ieved with a prevention modality (or combination) that achieves
extremely high effectiveness at a population level. Vaccines are the
only prevention modality that do not rely on sustained behavior-
modiﬁcation, which are known to be able to achieve this high de-
gree of effectiveness. Although initial HIV/AIDS vaccines may not be
so highly effective, efforts to develop such highly effective vaccines
must continue. Even partially effective HIV/AIDS vaccines may have
a positive impact on a population level [3].
4. History of clinical development of HIV/AIDS vaccines
The clinical development of candidate HIV/AIDS vaccines began
in the late 1980s. Since that time, more than 100 candidate
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conducted in countries worldwide. Some candidates have moved
forward to Phase 2a studies, but few have advanced to the stage of
Phase 2b or Phase 3 efﬁcacy studies [4]. Among those that have
been clinically tested for efﬁcacy, only one candidate regimen has
so far shown modest efﬁcacy. The remainder have failed to
demonstrate efﬁcacy and in one case, there was a trend towards
possible enhanced risk of acquisition of HIV infection, acquired
through risk behavior, in those vaccinated.
There are numerous scientiﬁc challenges to the development of
an HIV vaccine, as highlighted in the companion review. These
challenges have so far vexed the HIV vaccine development ﬁeld. As
the risk for failure involved in HIV vaccine development is so
considerable, industry has been reluctant to invest the tremendous
amounts of resources needed for such development without some
mechanisms to share the risk. As a consequence, publiceprivate
partnerships, public clinical trial networks, and public funding have
been central to progress in the ﬁeld.
4.1. International collaborative efforts to facilitate the clinical
development of HIV/AIDS vaccines
Due to the difﬁcult challenges for developing HIV/AIDS vaccines,
several publiceprivate partnerships and clinical trials networks
have taken up these challenges. The ﬁeld has recognized that no
one individual or organization is capable of overcoming so many
hurdles and that only through international collaborative efforts
may these challenges be faced. Listed below are several active
participants in these international collaborative efforts, including
donors, clinical trial networks, non-proﬁt organizations, advocacy
groups, and other important parties, including the WHO. For more
information on each, where appropriate, weblinks are provided.
Important players in the ﬁeld include:
 The WHO-UNAIDS HIV Vaccine Initiative and Other Relevant
WHO Initiatives
The WHO has played a critical role in advising countries on is-
sues relevant to the development of HIV/AIDS vaccines. The
WHO has held a number of consultations to facilitate informa-
tion sharing, to reach consensus, and to develop appropriate
guidance on topics covering ethics, inclusion of adolescents and
women in clinical trials, vaccine quality issues, non-clinical is-
sues and clinical issues important to HIV vaccines.
In addition to the efforts by the WHO, there is a WHO standing
AIDS Vaccine Advisory Committee (VAC), which has assisted
countries in the review of proposed clinical trials. The WHO
supports the African Vaccine Regulatory Forum (AVAREF),
which holds ongoing discussions that assist regulators across
Africa in the consideration of regulatory issues on HIV, malaria,
tuberculosis, and other vaccines of relevance to the continent.
The WHO supports the Developing Country Vaccine Regulatory
Network (DCVRN), which likewise meets regularly to discuss
regulatory issues with regards to vaccines of relevance to the 11
countries that participate in this network. The purpose of the
DCVRN is to contribute to the strengthening of the National
Regulatory Authorities (NRA) in low- and middle-income
countries where vaccines are manufactured, particularly in the
area of authorization and evaluation of vaccine clinical trials.
WHO-UNAIDS also developed the African AIDS Vaccine Pro-
gramme (AAVP), whose secretariat was transitioned to Uganda
in 2010.
Finally, the WHO has several Collaborating Centers, some of
which have clinical trials evaluation expertise and all of which
have laboratory expertise relevant to the manufacture of and
analytics for vaccines. More information may be obtained fromhttp://www.who.int/collaboratingcentres/en/ (accessed 11/17/
2014).
 The U.S. National Institutes of Health's (NIH) Division of AIDS
(DAIDS), the HIV Vaccine Trials Network (HVTN), Other
DAIDS-Funded Clinical Trials Networks (CHAVI-ID, HPTN,
IMPAACT), and the Vaccine Research Center
Undoubtedly, the largest funder of HIV vaccine research has
been the U.S. National Institutes of Health (NIH). In addition to
funding academic research as well as funding development by
biotechnology companies and large pharma/vaccine companies,
the Division of AIDS (DAIDS) at the NIH funds several clinical
trials networks, which perform clinical trials of candidate HIV
vaccines and other interventions developed by academicians, as
well as small and large industry. Among these, the greatest
number of vaccine trials has been conducted by the HIV Vaccine
Trials Network (HVTN) and its predecessor, the AIDS Vaccine
Evaluation Group (AVEG). The HVTN has clinical trials sites on
most continents. In addition, DAIDS funds the HIV Prevention
Trials Network (HPTN), which has performed important studies
onmicrobicides, post-exposure prophylaxis (PEP), pre-exposure
prophylaxis (PrEP), and other prevention interventions. Studies
undertaken with a focus on mother to child transmission
(MTCT) or on vaccination or prevention in infants, children, or
adolescents are the subject of the DAIDS' funded International
Maternal, Pediatric, and Adolescent AIDS Trials Network
(IMPAACT). More recently, DAIDS funded two Centers for HIV/
AIDS Vaccine Immunology and Immunogen Design (CHAVI-ID),
which will also be responsible in conducting clinical trials of
immunogens they have designed. Finally, but importantly, the
intramural NIH Vaccine Research Center conducts primary
research, as well as preclinical and clinical research with an aim
to develop a successful HIV/AIDS vaccine. Some of this research
will be reviewed below, particularly the regimen tested for ef-
ﬁcacy in HVTN 505.
 International AIDS Vaccine Initiative (IAVI)
Another donor, which is a global non-proﬁt organization, is the
International AIDS Vaccine Initiative (IAVI, www.iavi.org). This
organization supports the development of a number of potential
HIV/AIDS vaccine candidates and has clinical trial sites and
laboratories in several countries.
 The U.S. Military HIV Research Program (USMHRP)
The U.S. military has a long history in combatting tropical dis-
eases and in vaccine development. The USMHRP (http://www.
hivresearch.org/home.php, accessed 8/19/2013) has several
clinical trials sites with which they work in multiple countries
worldwide, as well as active laboratories and vaccine develop-
ment efforts.
 P5 e the Poxvirus-Protein PublicePrivate Partnership
As an outcome of the RV144 study, a Poxvirus-Protein Pub-
licePrivate Partnership (or P5; http://vaccineenterprise.org/
content/P5Partnership) was organized with the purpose of
extending the results of that critical efﬁcacy study. The P5 is a
collaboration between industry (Sanoﬁ Pasteur, Novartis, and
GlaxoSmithKline), the U.S. government (DAIDS and USMHRP),
the HVTN, and the Bill & Melinda Gates Foundation.
 The Bill & Melinda Gates Foundation (BMGF)
Another funder of increasing and signiﬁcant importance in the
arena of global health in general and in the development of
vaccines for several diseases of global importance, including
HIV/AIDS, in particular, is the Bill & Melinda Gates Foundation.
(http://www.gatesfoundation.org/, Accessed 2/28/2014) They
support basic and clinical research.
 The AIDS Vaccine Advocacy Coalition (AVAC)
An advocacy coalition that has played an important role in
public education, public policy and promotion of issues relevant
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cacy Coalition (AVAC). (http://www.avac.org/ Accessed 2/28/
2014)
 The Enterprise
The Global HIV Vaccine Enterprise was established at the sug-
gestion of a number of notable scientists from around the globe,
active in the HIV/AIDS vaccine ﬁeld. It was recognized that the
problem of HIV/AIDS vaccine development was so signiﬁcant
that no one organization or individual would be apt to solve the
problem working in isolation and that a large enterprise was
needed to coordinate and streamline global efforts. (http://
vaccineenterprise.org/ Accessed 2/28/2014)
 EuroVacc Foundation
Within Europe, one notable organization focused on the
development of HIV/AIDS vaccines is EuroVacc Foundation, a
non-proﬁt organization. (http://www.eurovacc.org/ Accessed 2/
28/2014) The Foundation supports basic, preclinical, and clinical
research.
 Agence Nationale de Recherche de la SIDA et les hepatitis
virales (ANRS)
French research agency that has developed and tested HIV/AIDS
vaccine candidates. (http://www.anrs.fr/, accessed 8/11/2015)
 Other National Initiatives, Advocates
The Ministry of Public Health, Thailand; TAVEG (Thai AIDS
Vaccine Evaluation Group); SAAVI (http://www.saavi.org.za/,
accessed 8/17/2013); KAVI (http://www.kaviuon.org/about_us.
php, accessed 8/17/2013); and Canadian HIV Vaccine Initiative
(CHVI, http://chvi-icvv.gc.ca/index-eng.htmlaccessed 11/25/
2013).4.2. More than 100 HIV/AIDS vaccine candidates have been tested
clinically
It is not for the lack of clinical candidates that so few have
advanced to efﬁcacy trials. In fact, HIV vaccine development, more
than any other vaccine ﬁeld, has driven the novelty of approaches
to immunogen design, delivery, and complexity. Initial candidates
were simple subunit approaches, particularly based on the en-
velope gene (env) in the forms of full length (gp160) and the
cleaved, soluble portion (gp120) or various truncated forms (some
soluble, some transmembrane-spanning, gp140, gp145, or gp150).
In addition to alum adjuvant, multiple novel adjuvants have been
tested with these protein immunogens. After testing simple
subunit vaccines, more complex designs were tried, including
peptides, lipopeptides, and vectors expressing various genes of
HIV. Vectors range from DNA plasmids, non-replicating viral
vectors, replicating viral vectors and bacterial vectors. Among the
non-replicating viral vectors are those that were deliberately
made to be non-replicating such as the Adenoviral vectors, with
gene deletions that preclude replication except in complementing
cell lines, and those that do not replicate in humans, such as
several of the poxvirus vectors, but which replicate in other
species' cells (e.g., chick embryo ﬁbroblasts). Summaries and lists
of prior candidates are published elsewhere (Jordan report;
http://www.niaid.nih.gov/topics/vaccines/Pages/Jordan2012.aspx)
[5].
One important feature of immunogen delivery that arose in the
effort to improve in vivo potency of vectored HIV/AIDS vaccines was
the heterologous prime-boost concept, in which one or more DNA
plasmids or one or more viral vectors serve for the initial priming
doses followed by, respectively, a or another viral vector(s) or
protein subunit(s), which serve as the subsequent boosting im-
munogen(s). Other diverse methods for immunogen delivery
included the use of novel delivery devices, such as the Biojector, orinclusion of electroporation or facilitators (e.g., bupivacaine) with
DNA plasmid delivery to facilitate uptake in vivo.
The diversity of approaches that have been tested pre-clinically
and clinically for HIV vaccine candidates is considerable, but many
Phase 1 studies failed to demonstrate the promise of the approach
that the pre-clinical data suggested and development of most
candidates has been abandoned. This illustrates the limitations of
the pre-clinical animal models, which as yet are not predictive of
clinical success. It would seem that the lack of immunogenicity in
an animal model may be predictive of a lack of clinical activity, but
potent immunogenicity, or even evidence of efﬁcacy, in animal
models has not fully been evidenced with clinical promise. Thus,
human clinical trials are presently the only way to truly determine
whether an HIV vaccine candidate will have activity or efﬁcacy in
humans. Regulators should appreciate this fact when considering
what amount and types of preclinical data to expect in review of a
CTA.
As a consequence of lack of signiﬁcant immunogenicity in Phase
1 (or in rare cases, adverse safety signals), only a limited number of
approaches have emerged to advanced clinical development. Those
that have been tested clinically for efﬁcacy are described below. As
stated above, the important lesson in the HIV vaccine ﬁeld is that
the pre-clinical models, though useful tools for many purposes,
have yet to achieve the ability to predict which vaccine(s) will be
efﬁcacious in humans, with the most potent of approaches that
have yielded promising efﬁcacy data in animalmodels having failed
to recapitulate this promise in clinical efﬁcacy testing. Thus, it must
be recognized that until the clinical efﬁcacy trials are performed
and the results become known, no one can know whether a
particular immunologically-promising candidate vaccine, regimen,
or design will yield clinical efﬁcacy. However, work must continue
to improve upon the animal models because human efﬁcacy
studies are expensive in many terms of various types of resources,
particularly human resources, but also ﬁnancial resources and
materials and laboratory capacity. No one wishes to place human
trial subjects at risk with no possibility of beneﬁt, so some means
must be used to identify the most promising candidates to move
forward. This remains one of the biggest scientiﬁc hurdles in the
HIV vaccine ﬁeld.
4.3. Phase 2b or Phase 3 efﬁcacy studies
This section of the review describes the six clinical efﬁcacy trials
that have been completed to date and their results, as well as les-
sons learned relevant to regulators. Each study was performed
because promising early pre-clinical and clinical data supported
moving forward into advanced development. Though essentially in
every case, the exact promise of those early clinical data (and pre-
clinical data) were controversial among those working in the ﬁeld.
These controversies reﬂect the scientiﬁc uncertainties in the ﬁeld.
Each study was justiﬁed based on certain existing data at the time
they were initiated. These data include safety and immunogenicity
data from earlier human clinical trials, as well as efﬁcacy (chal-
lengeeprotection) data in some non-human primate models. In
point of fact, perhaps the most controversial of these efﬁcacy
studies was the RV144 study, which, as it turned out, was the only
study to demonstrate modest efﬁcacy, while other candidates
thought to be the most promising at any given time had no efﬁcacy
in humans. This underscores the scientiﬁc challenges to developing
an effective HIV/AIDS vaccine and the uncertainties that exist
within the ﬁeld and why we must be humble and agnostic as sci-
entists when considering CTAs.
Nonetheless, regardless of the ultimate outcomes of the studies,
each was conducted in compliance with Good Clinical Practices
(GCP) and appropriate ethical standards. Each was well-performed,
Local edema Induration Subcutaneous nodule
Vaccinees 36% 29% 21%
Placebo recipients 17% 15% 12%
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AIDS vaccine efﬁcacy studies were feasible and could be conducted
with good recruitment and retention. Positive lessons were learned
in the conduct of each study and those lessons were built upon in
subsequent studies.
The lack of clear-cut and obvious scientiﬁc criteria to support
advancement into efﬁcacy testing is a difﬁculty that regulators
must be cognizant of and grapple with in their review of CTAs for
efﬁcacy studies. Experts in the ﬁeld are uncertain and disagree
among themselves about which candidates warrant advancement.
Thus, regulators should recognize that they can hardly be expected
to know for certain, when foremost authorities on the subject do
not.
One should not become too overly concerned with the
nomenclature of Phase 2b or Phase 3, or pilot or pivotal, when
considering HIV/AIDS vaccine efﬁcacy studies. The important
regulatory consideration, rather than this nomenclature, is
whether or not the efﬁcacy study as designed would support
licensure or registration, as a sole efﬁcacy study or as one of two
or more efﬁcacy studies of that vaccine candidate or regimen. The
important facet for a licensure trial is the power the study has to
credibly establish efﬁcacy and the primary claims for labeling of
that vaccine candidate or regimen. Another important regulatory
consideration would be, in terms of correlates of protection,
whether the study would be designed to be hypothesis-generating
or hypothesis-testing. However, correlates of protection are not
necessarily required for licensure of an efﬁcacious vaccine,
although they greatly facilitate vaccine development. So, whatever
the efﬁcacy study is called, its design should be considered in
review of the CTA, as to whether the regulator would consider it
as means to identify hypotheses to be later tested in a pivotal,
licensure-supporting trial, or whether it tests appropriate
licensure-supporting hypotheses and is itself sufﬁcient to support
licensure (registration) decisions. A clear understanding between
regulators and applicant(s) should be in place when the regulators
allow the trial to proceed, to prevent being faced with too few
data upon which to make a meaningful licensure (registration)
decision at the study's completion.
To date, none of the efﬁcacy studies that have been conducted
have supported the licensure of an HIV/AIDS vaccine regimen solely
on their own merit. However, it will be noted below whether the
intent of the studies at their outset was to be licensure-supporting
(pivotal) or pilot (Phase 2b) studies to guide further clinical
development.
4.3.1. VAX004
The VAX004 studywas conducted by VaxGen from 1998 to 2003
in North America and the Netherlands, primarily in HIV-uninfected
MSM, but also included high-risk heterosexual women. The
candidate vaccine was a bivalent clade B gp120 subunit vaccine
adjuvanted with alum. Individuals using intravenous drugs (IDU or
PWID) were not enrolled in this study. This Phase 3 study was
performed with intention to support licensure, in conjunction with
the VAX003 study described below, which enrolled IDU or PWID.
Individuals were randomized 2:1 to receive vaccine (300 mcg each
of MN gp120 and GNE8 gp120 adsorbed onto 600 mcg alum) or
placebo (alum). Vaccinations were given at months 0, 1, 6, 12, 18, 24
and 30, with the ﬁnal study visit at month 36. HIV status was
assessed by standard HIV-1 ELISA and conﬁrmatory immunoblot.
Time of infection was estimated to be the midpoint between the
last negative ELISA and immunoblot and the ﬁrst positive one. HIV
plasma RNA was also measured. The date of infection may have
been taken as the ﬁrst date when a positive RNA sample was
measured. For volunteers who became infected on the study (from
their own risk behavior despite extensive risk reductioncounseling), CD4 counts and viral load (plasma RNA) were
measured at <1, 1, 2, 4, 8, 12, 16, 20, and 24 months post-diagnosis.
Questionnaires on self-reported risk behaviors were performed at
baseline and every six months. Viruses from infected individuals
were sequenced. All isolates except 1 were clade B. The exception
was clade C. Immunogenicity was evaluated by neutralization
against MN and binding antibodies by ﬁve indirect ELISAs to MN/
GNE8 gp120 mixture, GNE8 V2, MN V2, GNE8 V3, and MN V3. A
further two competitive ELISAs were conducted to measure
blocking antibodies against either MN or GNE8, with soluble CD4.
These analyses were performed two weeks after the last immuni-
zation before infection occurred and two weeks after every im-
munization on a random 5% subset.
The primary endpoint of the study was Vaccine Efﬁcacy [VE;
(1  relative risk of infection)  100]. The time to HIV infectionwas
grouped by six month intervals. The study was designed to have
90% power to reject a null hypothesis of VE 30% if the true VE was
60%. Secondary endpoints related to viral loads before initiation of
anti-retroviral therapy (ART) and time-to-initiation of ART between
the two study arms. Exploratory analyses were performed on de-
mographic factors, such as age (30 or >30), race (white, black,
Hispanic, Asian, or other and white vs. non-white), gender, edu-
cation (less than a college degree or college or graduate degree),
and baseline behavioral risk (high, medium, low).
Between June 1998 and October 1999, 7185 subjects were
screened and 5417 eligible subjects enrolled (5108 men and 309
women). Despite negative baseline HIV antibody screening, 14
subjects were subsequently found to be HIV-infected at baseline
and were excluded from efﬁcacy analyses. 11 of these were enrolled
into the vaccinee group and three into the placebo group. 368
volunteers became infected on the study (through their risk
behavior) for an annualized rate of 2.6% (2.7% in men and 0.8% in
women). Only six women became infected during the study.
Controversy to initiate this study arose when, in 1994, in an
open public meeting at the National Institutes of Health (NIH), the
NIH decided not to advance either VaxGen's or Chiron/Biocine's
gp120 candidate vaccines into efﬁcacy testing because, while they
each generated strong binding antibodies and strain-speciﬁc
neutralizing antibodies, they did not generate antibodies that
could broadly neutralize multiple clade B strains by the latest
assay methods. Because of the variability of HIV, concern arose
over the utility of strain-speciﬁc neutralization to protect against
the broad array of viruses that would be encountered by partici-
pants in an efﬁcacy trial (through their high risk behaviors).
VaxGen, nonetheless, spent the subsequent years gathering
funding and resources to initiate both the VAX004 and VAX003
studies (to be described below) without signiﬁcant support from
NIH funding.
Some information in this section and subsequent sub-sections
has been taken from the publication of the efﬁcacy study results
in the article by the rgp120 HIV Vaccine Study Group [6]. Infor-
mation has been paraphrased or sometimes directly quoted.4.3.1.1. Safety. The vaccinations were stated to be well-tolerated.
Most common events were mild to moderate in the ﬁrst three
days following vaccination. Rates of local symptoms were higher in
vaccinees than placebo-recipients, as follows, as reported on one of
14 days following vaccination:
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or types of reported adverse experiences between groups.
4.3.1.2. Immunogenicity. All vaccinees developed antibodies
against gp120. Vaccinees with higher antibodies that were MN
CD4-blocking, GNE8 CD4-blocking, and MN neutralizing tended to
have a lower rate of HIV infection. Virus sequences were analyzed
to determine whether there was a differential impact of those that
contained the same V3 domain sequences as the vaccine (GPGRAF)
and those that did not. This selective pressure has also been
referred to as a “sieving effect.” Overall, there was no evidence of
this effect with 0% VE among those infected with GPGRAF-
containing and 19% VE in those infected with viruses that did not
contain that sequence. However, there was a non-signiﬁcant trend
to an estimated VE of 73% in non-whites with viruses with the
GPGRAF sequence (95% CI: 35e88%) vs. an estimated VE of 24% in
those infected with viruses without this sequence (95% CI: 59 to
63%) for a p-value of 0.077.
4.3.1.3. Efﬁcacy. Efﬁcacy was not observed [VE 6% (95% CI 17 to
24%), p ¼ 0.59]. KaplaneMeier curves revealed equivalent
approximately constant rates of infection over 36 months. Pre-ART
viral loads were similar in both groups (p¼ 0.81). Rates of initiation
of ART were similar between groups (p ¼ 0.61). There were no
interactions noted for efﬁcacy with age, gender, or education levels.
However, for baseline risk levels, VE varied signiﬁcantly (p ¼ 0.041)
with VE decreasing in the highest risk group and by race (p¼ 0.007)
with lower VE in Caucasians (“whites”) than in other racial groups
(“non-whites”).
4.3.1.4. Lessons learned relevant to regulatory evaluation.
Controversy was raised by discordant announcements in the press
over the outcome of the study because of the sub-group analyses
that suggested that while there was no efﬁcacy in the overall
population, there appeared to be efﬁcacy in “non-whites.” The
press either reported that the study demonstrated efﬁcacy or more
correctly, that it did not. However, a lesson learned from this
experience relevant to regulators is the need for sponsors to be
clear in the statistical analysis plan about when to continue to
analyze sub-groups when efﬁcacy overall was not seen and
whether these additional analyses will be hypothesis-testing or
hypothesis-generating. The study sponsors had prospectively
planned the sub-group analyses, but it may have been a regulatory
expectation that claims would not be made on the basis of these
tertiary analyses, when the primary analysis did not refute the null
hypothesis. Thus, regulators should clearly articulate their expec-
tations when reviewing a sponsor's statistical analysis plan, in
regards to claims made regarding the study's outcome. The sub-
group analyses were appropriate as hypothesis-generating, given
the failure of the primary analysis. If the primary analysis had been
positive, then claims might be considered on the basis of the sec-
ondary analyses or possibly even tertiary analyses. However, when
the primary analysis is negative, caution in interpreting secondary
and tertiary analyses must be taken.
The other controversial statistical issue raised with the report-
ing of study results came from the lack of statistical adjustments
taken as a result of the multiplicity of analyses performed. Statis-
tical adjustments, like the FlemingeO'Brien approach, should be
incorporated into the statistical analysis plan and reports of sta-
tistical signiﬁcance should note whether or not the p-value has
been adjusted, accordingly.
4.3.2. VAX003
TheVAX003 studywas conducted byVaxGen and theMinistry of
Public Health of Thailand from 1999 to 2003, in Thailand inintravenous drug users (IDU or PWID). This Phase 3 trial was con-
ducted to provide additional evidence to support licensure by hav-
ing twowell-controlled efﬁcacy studies indifferent risk populations.
However, as the circulating strains in Thailand differ from those in
North America, the bivalent vaccine contained not only the clade B
MN strain (300 mcg), but also the clade E (recombinant A/E clade)
A244 strain gp120 (300 mcg), adjuvanted in alum (600 mcg). The
placebo consisted solely of alum. The study was randomized 1:1
vaccinees to placebo-recipients. HIV-uninfected volunteers aged
20e60 who had used intravenous drugs in the past year and were
being treated at one of 17 Bangkok methadone treatment clinics
were enrolled. For females to enroll, they could not be pregnant or
breast-feeding and had to agree to use contraceptionwhile on study
to reduce possible risks to fetuses. To ensure comprehension of the
trial procedures andwhat theywere volunteering to do in the study,
potential volunteers had to pass two written trial comprehension
tests. Volunteers received extensive risk reduction counseling at
study visits. Condoms and bleach to sterilize injection equipment
were provided to volunteers free of charge.
Like the VAX004 study described above, self-reported behav-
ioral risk questionnaires were administered at baseline and every
six months during the study. Vaccinations were given at 0, 1, 6, 12,
18, 24, and 36 months. The HIV status was judged by ELISA and
conﬁrmatory immunoblotting requiring at least two non-gp120
bands to be positive. HIV plasma RNA was measured in in-
dividuals evidencing seroconversion to HIV infection. If RNA was
negative, the date of infection was estimated to be the midpoint
between the last negative and ﬁrst positive ELISA/immunoblot.
Otherwise, the date was taken as the ﬁrst RNA positive visit. Vol-
unteers who became infected (by their own risk behavior) on study
were followed at <1, 1, 2, 4, 8, 12, 16, 20, and 24 months for plasma
RNA levels and CD4 and CD8 cell counts. Five immunogenicity
ELISAs were performed for volunteers at either twoweeks after the
last immunization at which the volunteer remained HIV-
uninfected or in a random subset of volunteers at each immuni-
zation and two weeks after the last immunization (10% of unin-
fected vaccinees and 1% of uninfected placebo-recipients). Viral
sequences were obtained from infected individuals.
The primary study endpoint was acquisition of HIV infection.
Secondary endpoints were safety and delay to disease progression,
as judged by clinical endpoints (time to initiation of ART or AIDS-
deﬁning illness onset) and virological and cellular endpoints.
Some information in this section and subsequent sub-sections
has been taken from the publication of the efﬁcacy study results
by Pitisuttithum et al. [7]. Information has been paraphrased or
sometimes directly quoted.
4.3.2.1. Safety. Tenderness at the injection site was reported in 71%
of vaccinees and 65% of placebo-recipients and did not increase
with repeated inoculations. Of 414 Serious Adverse Events (SAEs)
reported, the majority were accidental injury (128) and drug
overdose (49), with sepsis occurring in 22 cases, with no differ-
ences in rates between groups. Likewise, among the 102 deaths, 38
were due to drug overdose, 17 to sepsis, 12 to accidental injury, and
8 to suicide, with no differences between groups.
4.3.2.2. Immunogenicity. There were no signiﬁcant differences be-
tween infected vaccinees and randomly selected uninfected vac-
cinees in pre-infection antibodies (in infected vaccinees) or
antibodies (in uninfected vaccinees) as measured by binding to
gp120, A244 V2, A244 V3, blocking of A244 to CD4, or neutraliza-
tion of MN. Antibodies were seen in all vaccinees in which they
were measured and in no placebo recipients in which they were
assessed (n ¼ 12). Geometric mean neutralization titers after a
complete primary immunization series (month 6.5) were 3972 and
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boosting immunization periods, reaching as high as 5707 at month
12.5.
4.3.2.3. Efﬁcacy. There were no differences in the time to HIV
acquisition through risk behavior between the two groups, with
106/1267 vaccinees and 105/1260 placebo-recipients becoming
infected on study. Efﬁcacy was estimated at 0.1% with a 95% con-
ﬁdence interval of 30.8 to 23.8 and p ¼ 0.99 (log-rank test).
Likewise, no signiﬁcant differences were seen in clinical endpoints
in the infected, nor virological or cellular endpoints.
4.3.2.4. Lessons learned relevant to regulatory evaluation.
Occasionally, people (including regulators) may pre-suppose that
certain populations who are at highest risk of HIV infection by
virtue of being a member of a marginalized community, e.g., IDU or
PWID; are difﬁcult, if not impossible, to recruit and retain in a
clinical trial. VAX003 showed that it was feasible to successfully
conduct a study in such a population and it required the political
will of the Thai government to facilitate this happening in this
study. In general, regulators know the political situation in their
own countries much better than might applicants. Discussions on
potential barriers to conduct a trial should follow review of the
protocol, given the political situation in one's country or particular
communities and should be considered between regulators and
applicants to ensure the potential for a trial being approved, to be
successfully conducted. Neither trial sponsors nor regulators
beneﬁt from a trial that fails to give a clear and credible answer.
Working collaboratively, trials can be designed and conducted
successfully, even when conducted in populations that might, on
ﬁrst impression, seem difﬁcult or impossible to even consider. As
the HIV/AIDS epidemic does affect many such marginalized pop-
ulations, it would be a disservice at best and unethical at worst to
ignore these populations when conducting HIV/AIDS vaccine efﬁ-
cacy studies.
4.3.3. STEP
This study was designed as a Phase 2b test-of-concept study and
originally was designed to enroll only Ad5-seronegative subjects,
but was later expanded to enroll Ad5-seropositive subjects. The
concept being tested was whether a T-cell-inducing vaccine not
expected to elicit antibodies of signiﬁcance (e.g., against the en-
velope gene product, whichwas absent from the vaccine candidate)
could have efﬁcacy. The study was conducted by Merck Research
Labs (http://www.merck.com/index.html, accessed 8/19/2013,
USA) and by the HVTN in Australia, the Caribbean, and North and
South America. The study product was a trivalent replication-
incompetent Adenovirus type 5-vectored vaccine candidate
expressing clade B HIV-1 gag, pol, and nef genes on a 0, 1, 6 month
schedule at a dose of 1.5  1010 vector genomes (equivalent to a
prior dose used of 3 1010 viral particles) in 1mL. Enrollment in the
seronegative population began in December 2004 and in July 2005,
enrollment was expanded to Ad5-seropositive subjects with a
target goal of 1500 of each. Seropositivity to Ad5 at baseline was
deﬁned as a reciprocal titer of 200. Participants were enrolled
until March 2007. Trial subjects were 18e45 years of age. Different
risk criteria permitted enrollment of men [MSM who had unpro-
tected anal sex or anal sex with two or more partners in the prior
six months, heterosexual men in Caribbean sites who had a history
of particular STDs, exchanging sex for money or other commodities,
use of crack cocaine, ormultiple sexual partners (two ormore in the
prior six months)] or heterosexual women (who had unprotected
sex with a partner known to be HIV-infected or an IDU, who used
crack cocaine, or who exchanged sex for money or other
commodities).The endpoints of the study were safety and tolerability, as well
as the following efﬁcacy endpoints in the original trial population
(Ad5-seronegative at baseline): acquisition of HIV infection and the
average of viral load (plasma RNA) taken at two and three months
post-diagnosis of infection. The per-protocol analysis considered all
subjects who received their ﬁrst two doses of study treatment to
which they were randomly assigned and who were not diagnosed
as infected until after week 12 on study, and did not violate the
protocol. The MITT population included all those who received at
least one study treatment and who were not HIV-infected at
baseline, before randomization. Secondary endpoints were to
evaluate safety, tolerability and efﬁcacy in the entire study popu-
lation regardless of baseline serostatus to Ad5 and to identify im-
mune correlates of efﬁcacy. Exploratory endpoints included
interactions between the two primary efﬁcacy endpoints and
prognostic factors between demographics and efﬁcacy (e.g., gender,
baseline Ad5 serostatus, age, circumcision status in men, etc.). The
study was designed and powered as an event-driven analysis, with
the expectation of acquiring 50 endpoints (HIV infection) in each
serostatus group, with a planned interim analysis at 30 endpoints.
The sample size gave an 80% power to detect a 60% reduction in
HIV acquisition or1 log10 difference in set-point viral load in favor
of the vaccinated group compared to the placebo-recipient group.
Futility criteria were also established. At the interim analysis, if the
1-sided p-value was >0.5 for both efﬁcacy endpoints, the vaccine
would be declared ineffective and the study halted early for futility.
Additional analyses were added because the study did unexpect-
edly meet the criteria for futility. These additional analyses are
described in Buchbinder et al. [8]. The Data SafetyMonitoring Board
(DSMB) met in September 2007, reviewed unblinded data and
recommended halting the study for futility.
Three thousand subjects were enrolled in the study, with 1515 of
low Ad5-serostatus enrolled and 1485 Ad5-seropositive enrolled.
More than 90% of vaccinees received all three inoculations. About
30% of the enrolled participants of low Ad5-serostatus were female
and nearly 50% of Ad5-seropositive participants were female, but
only one infection occurred in a woman, so most efﬁcacy analyses
were performed considering the infections in men only. Forty-ﬁve
infections occurred during the study in the population that
received at least one inoculation and who was not retrospectively
found to be HIV-infected at baseline.
Like the earlier trials, this study met some controversy as well,
because it was expanded into a larger population (the Ad5-
seropositive population) before efﬁcacy results in the “best-case
scenario” (Ad5-low serostatus) population were known. Immuno-
genicity data from the Ad-5 seropositive population from earlier
phase studies became available after the initial STEP study had
begun. These data supported a robust cellular response to the
vaccine insert genes in the face of pre-existing vector immunity, so
the decisionwas made by the trial sponsors to expand the study on
the basis of those immunogenicity results.
Some information in this section and subsequent sub-sections
has been taken from the publication of the efﬁcacy study results
by Buchbinder et al. [8]. Information has been paraphrased or
sometimes directly quoted.
4.3.3.1. Safety. Pain at the injection site was reported in 49% of
vaccinees and 21% of placebo-recipients and headache was re-
ported in 22% of vaccinees and 18% of placebo-recipients. These
were the most common adverse experiences. Safety laboratory
results were not different between vaccinees and placebo-
recipients. There were 40 SAEs (not including HIV infections), but
only two (fever, rigors) were deemed study product-related.
As will be described below for efﬁcacy, there was a trend in the
increased number of HIV infections in vaccinated subjects who
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lyses reached statistical signiﬁcance. Thus, although still not fully
explained biologically and despite extensive efforts to determine a
mechanism, it appears that boosting a pre-existing anti-vector
cellular immune response to Ad5 with the vectored-vaccine
enhanced HIV infectiousness to vaccinees upon exposure from
risk behaviors. More discussion on this adverse safety outcome of
the STEP study will be described in the efﬁcacy section below.
Similarly, see Section 4.3.7 on the NIHMini-Summit on Adenovirus-
vectored HIV vaccines for more on this safety issue.4.3.3.2. Immunogenicity. Because of the complexity of collecting,
processing, storing, handling, and analyzing appropriate samples
for T-cell analyses, it was prospectively planned that a randomly
selected 25% of participants would have such analyses performed.
Of the 354 participants (including both seropositive and seroneg-
ative participants) whose samples were collected for this purpose,
75% of vaccinees produced gamma-interferon ELISpot responses
against one or more of the vaccine antigens. ELISpot analyses were
performed on samples taken at weeks 8 and 30, subsequent to the
2nd and 3rd doses of vaccine. Table 2 of the Buchbinder article
provides the immunogenicity results from the STEP study. Themost
frequent responses were against the Gag antigen, with 75% of the
Ad5-seronegatives responding and 54% of the Ad5-seropositives
responding. 84% of the Ad5-seronegatives and 68% of the Ad5-
seropositives responded to 1 or more antigens. The strongest re-
sponses were seen to the Pol antigen, with GMT of 489 in the Ad5-
seronegatives and 245 in the Ad5-seropositives. While Ad5 pre-
existing immunity did blunt responses against the vaccine anti-
gens, the majority of subjects still responded with reasonable
robustness. Whether this less robust response in the Ad5-
seropositives contributed to the apparent enhanced risk of acqui-
sition in this sub-group is unknown, but was among the many
factors considered when trying to understand a possible mecha-
nism of action and risk factors for the apparent enhancement seen.
Consideration of an immunemechanism of actionwas also given to
the role of immune activation, by the vaccination series, of CD4 T
cells, which could be the target of HIV infection, at mucosal sur-
faces. See the publication on the proceedings of the NIH Mini-
Summit described in Section 4.3.7 below.4.3.3.3. Efﬁcacy. As stated above, the primary efﬁcacy endpoint for
the study was focused on the population that was Ad5-
seronegative at baseline, i.e., the original trial population. This
was, in fact, a co-primary endpoint, of infection rates or viral load
(average of two measures taken approximately three months after
infection) or both. Efﬁcacy in the entire study population was a
secondary endpoint. An assessment of associations between the
primary endpoints and prognostic factors was planned as a tertiary
endpoint. Prognostic factors included gender, anti-Ad5 titer at
baseline, age, ethnicity, HLA type, and circumcision status (in men).
The per-protocol population had 29 infections inmen and one in
a woman. This woman received the placebo. Further analyses thus
focused solely on infections in men. In men, there were 19 in-
fections in the vaccine group and 10 in the placebo group
(p ¼ 0.949). The mean viral load set-points in these men were
4.6 log10 copies/mcL in the vaccinated group and 4.57 log10 copies/
mcL in the placebo group (p¼ 0.528). In the MITT population, there
were 45 infections: one in the womanwho received the placebo, 24
in vaccinated men and 20 in men who received the placebo
(p ¼ 0.743). Mean viral load set-points were 4.61 log10 copies/mcL
in the vaccinated men and 4.41 log10 copies/mcL in the men who
received the placebo (p ¼ 0.656). All p-values reported were one-
tailed assessing vaccine beneﬁt.Given the lack of efﬁcacy and the higher rate of infections in the
vaccine arm of the study, the tertiary analyses of association
became exceedingly important as hypothesis-generating. Doing so
permitted the attempt to understand whether there was a sub-
population of vaccinated individuals who were at increased risk
of HIV acquisition or whether there was simply a lack of efﬁcacy.
While these analyses identify only associations and do not test
whether the associations are causal, they can shed light on poten-
tial modes of action. First, univariate Cox proportional-hazard
models were used to quantify treatment effects in the four sub-
groups based on the original stratiﬁcation by baseline Ad5-
serostatus. These analyses were shown in Table 4 of the Buch-
binder article. The overall hazard ratio for treatment effect was 1.5
(95% CI 0.97e2.3, p ¼ 0.07). The interaction of vaccine or placebo
and baseline Ad5-serostatus showed a trend (p ¼ 0.08). The inter-
action of vaccine or placebo and circumcision status was statisti-
cally signiﬁcant (p ¼ 0.01). The authors urged caution in
interpretation however, as subjects were not randomly assigned
based on circumcision status. In fact, men who were Ad5-
seropositive were much more likely to be uncircumcised than
those who were Ad5-seronegative. Race, age, and geography did
not show signiﬁcant interactions. Likewise, behavioral risk factors
did not show signiﬁcant interactions with vaccine or placebo
among those who became infected through their risk behaviors.
Time-to-event was deﬁned as the time of the original vaccination
(or placebo inoculation) to the midpoint between the date of the
last visit at which a subject remained HIV-seronegative and the ﬁrst
positive visit (based on ﬁrst evidence of HIV infection). Further,
groups were deﬁned by quadrants of serostatus: Ad5 titers of 18
(essentially seronegative), 19e200, 201e1000, and >1000.
KaplaneMeier curves were plotted and are shown in Figure 2 of the
Buchbinder article. Treatment effects were quantiﬁed with esti-
mated Wald-based 95% CI and two-tailed p-values. Finally, multi-
variate Cox models were used to estimate treatment effects after
adjusting for dichotomous confounding factors. Hazard ratios were
calculated between those who received vaccine and those who
received placebo for the four sub-groups of being Ad5-seronegative
and circumcised, Ad5-seronegative and uncircumcised, Ad5-
seropositive and circumcised, or Ad5-seropositive and uncircum-
cised. The results were respectively, 0.7 (95% CI 0.3e1.4), 3.3 (95% CI
0.7e15.8), 1.6 (95% CI 0.7e3.8), and 3.9 (95% CI 1.3e11.9).
One facet that warrants discussion is that while the rates of HIV
acquisition in most sub-groups was on the order of about 4%, in the
placebo-group of Ad5-seropositives, the rate was almost half this.
The contribution of this fact to the analysis cannot be ignored.
However, the hazard ratios increased with increasing Ad5 titers,
suggesting these ﬁndings were not simply an effect of this statistic.
Although the risk of HIV acquisition between vaccinees and
placebo recipients did not associate with serostatus for HSV-2,
being seropositive for HSV-2 independently associated with the
risk of HIV acquisition, regardless of vaccination or placebo receipt.
Among 88 men who became infected with HIV through their risk
behaviors during the STEP study, 33 vaccinees were HSV-2-
seronegative, 18 placebo-recipients were HSV-2-seronegative, 19
vaccinees were HSV-2-seropositive and 17 placebo-recipients were
HSV-2-seropositive. Pre-existing HSV-2-seropositivity was associ-
ated with increased acquisition of HIV among placebo-recipients
(p ¼ 0.019) with a HR of 2.2 (95% CI, 1.1e4.2) and among all trial
participants (p ¼ 0.009) [9].
A “sieve” analysis was also performed for this study and found
that breakthrough infections in vaccinees had sequences that were
more divergent from the vaccine insert than did the viruses with
which the placebo-recipients were infected, suggesting that the
immune response did play some role, although it did not result in
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acquisition [10].
4.3.3.4. Lessons learned relevant to regulatory evaluation.
Despite being possibly the most potent candidate vaccine at the
time, which elicited good cellular responses in a signiﬁcant per-
centage of participants of the STEP study, the T cell responses alone
elicited by this vaccine regimen were insufﬁcient to prevent
acquisition of the HIV infection. Further, it was expected that
cellular immunity elicited by vaccinationwould result in decreased
viral load among those who did become infected and yet, this was
not seen in this study either. Regulators should note that while an
applicant should provide immunological justiﬁcation or a proposed
mode ormechanism of action for their vaccine candidate to support
conducting clinical trials, for HIV/AIDS vaccines, the ﬁeld still does
not know which types and quantities of immune responses are
required for protection. Not only is there no known correlate of
protection, but even the immunological mechanism whereby a
vaccine might protect, either by preventing acquisition or by
modulating disease in thosewho become infected, is still unknown.
When reviewing a CTA, consideration of this lack of knowledge
must be taken.
Another relevant lesson learned from the STEP study is that the
previously only hypothetical potential for enhanced risk of HIV
acquisition is in fact, not simply hypothetical. It is also hypothetical
(and this potential risk should and does appear in informed consent
forms) that vaccination could paradoxically enhance disease pro-
gression in those who subsequently become infected. While this
was not seen in the STEP study, only additional follow-up and time
will tell. The consequences of these ﬁndings and both the demon-
strated and hypothetical risks are that trial participants need to be
informed of such risks. In reviewing CTAs, the informed consent
process and forms should convey the potential risk for a vaccine to
paradoxically harm, rather than protect, the participant by
enhanced risk of infection through risk behavior or enhanced risk of
disease progression in those who become infected.
Potential consideration should be given to use of one-tailed vs.
two-tailed p-values in the analysis of efﬁcacy. In the STEP study,
one-tailed p-values were considered assessing vaccine beneﬁt, but
given the results, it may have been more appropriate to consider
two-tailed p-values in which beneﬁt or harm are equally consid-
ered. Regulators should have that discussion with clinical trial
sponsors and come to an agreement on the appropriate statistical
plan before a study is unblinded and the data analyzed. Also, sta-
tistical plans for analyzing associations between efﬁcacy endpoints
and potential factors that might prognosticate risk of infection
should be clear prospectively. This is to permit identifying both
potential sub-groups in whom efﬁcacy may be greater and in the
event of lack of efﬁcacy, in whom enhanced risk may have been
seen. Doing so permits conducting subsequent trials in safer and
more appropriate populations and avoiding populations who may
be at enhanced risk. This helps to balance risk with potential for
beneﬁt in subsequent trial designs.
4.3.4. Phambili
Phambili (pam-bee-lee) was a companion study to the STEP
study and was also denoted HVTN 503. The name is Zulu for “For-
ward!” denoting the urgency to press forward with development of
an HIV/AIDS vaccine. The Phambili study was performed in South
Africa and enrolled sexually active men and women aged 18e35 in
the general population, at risk due to the high prevalence in that
country. The vaccine used in Phambili was the same as that used in
STEP, with the same doses and regimen. The Phambili study was
also intended to be a test-of-concept study (extending the concept
to non-clade-matched regions).The vaccine candidate only encoded internal viral proteins (the
capsid protein, Gag, and the polymerase) and a regulatory non-
structural protein (Nef) from Clade B. Because of this, it was felt
that the degree of conservation among clades for these proteins,
which do not experience as much immune pressure to vary as do
the Env proteins on the outside of the virus, was sufﬁcient to be
useful in the predominately Clade C geography. Furthermore, the
study population has a high degree of seropositivity against the
vector, Ad5, with many seropositives having higher titers than in
geographies where there is lower seropositivity in the population.
This study was also a Phase 2b test-of-concept efﬁcacy study, like
STEP. It was conducted by the HVTN with support fromMerck. This
study represented a very difﬁcult challenge for the vaccine, as
opposed to the original population in the STEP study, in which in-
dividuals did not have pre-existing immunity to the vector and the
vaccine candidate was clade-matched to the predominant circu-
lating HIV strains. In the case of Phambili, it was a cross-clade
“challenge” and individuals could theoretically have experienced
blunting of the immune response to the vaccine due to pre-existing
anti-vector immunity. However, this study population represents
one of the higher risk populations globally, reﬂecting a more “real-
world” situation for which the vaccine was tested. Phambili was
initiated before the results of the STEP study were known, and as
the name of the study implies, due to the urgency to press forward.
Enrollment was performed between January and September 2007
and was halted due to the interim analysis of the STEP study
revealing potential enhancement of HIV acquisition risk in Ad5-
seropositives in STEP. Thus, only 801 of the originally planned
3000 individuals were enrolled. This two-arm study randomized
1:1 vaccine to placebo.
The study was designed to be event-drivenwith the expectation
of observing 120 HIV infections in 3000 participants, giving 80%
power to detect: efﬁcacy against HIV acquisition of45%,0.75 log
difference in viral load at about two months and three months
(average) in those who did become infected, or both. Because of the
early halt to the study, the planned per protocol analysis was
rendered essentially meaningless (under-powered due to sample
size) and so a modiﬁed intent-to-treat analysis was used instead.
The MITT analysis included everyone vaccinated (vaccine or pla-
cebo) except those who were later determined to already be HIV-
infected at enrollment.
Of those enrolled, 400 received vaccine and 401 received pla-
cebo. Respectively (vaccine, placebo), 112 and 104 received only
their ﬁrst injection, 259 and 270 received their ﬁrst two injections
and only 29 and 27 received all three planned injections prior to the
early halting of the study. The study enrolled 441 men and 360
women. Reported in publication, there were 62 infections, 42 of
which were inwomen. More recent data from the study, which was
halted for vaccinations, but permitted continued follow-up of un-
blinded participants for safety, including HIV acquisition, has
revealed several more infections; 61 in women and 39 in men.
Follow-up for infections and safety continued by re-enrolling par-
ticipants in a “roll-over” study.
The scientiﬁc controversies to this study were in regards to its
timing relative to the STEP study, i.e., before the results of the STEP
study, which enrolled the “best-case” population, were known and
to using a clade B vaccine candidate in a population at risk of clade C
infections, as discussed above.
Some information in this section and subsequent sub-sections
has been taken from the publications of the efﬁcacy study results
by Gray et al. [11,12]. Information has been paraphrased or some-
times directly quoted.
4.3.4.1. Safety. Table 2 in the Gray et al. (2011) [11] publication
outline safety data from the Phambili study. Brieﬂy, the most
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tenderness occurred in 62% of vaccinees and 33% of placebo-
recipients. Any systemic reactogenicity occurred in 66% of vacci-
nees and 55% of placebo-recipients, with headache (46% vs. 37%)
and malaise or fatigue (39% vs. 29%) being the most frequent of
these. Reactogenicities that reached statistical signiﬁcance in dif-
ferences between the two arms of the studywere the local pain and
tenderness (p < 0.0001), headache (p ¼ 0.01), malaise or fatigue
(p ¼ 0.06), myalgia (p < 0.0001), and arthralgia (p ¼ 0.03). Sever-
ities were not reported in the publication. Among the non-
reactogenicity category of adverse events, none that were experi-
enced by participants reached statistical signiﬁcance in rates be-
tween the two arms of the study.
Pregnancies did occur during the study despite counseling to
use adequate birth control to prevent them. The rates did not differ
between study groups. Sexually transmitted infections, other than
HIV infection, were also reported in participants, occurring more
frequently in women (11.1 vs. 6.7 per 100 person years, p ¼ 0.007),
but occurring equivalently between study arms (7.5 vs. 9.8 per 100
person years) and before and after the trial was unblinded (9.9 vs.
9.6 and 7.7 vs. 9.9 per 100 person years).
Unlike the STEP study, statistical trends towards enhanced
acquisition of HIV infection in vaccinees who were Ad5-
seropositive at baseline or men who were uncircumcised were
not observed. But, it should be noted that the study was unpowered
signiﬁcantly by virtue of being halted early for enrollment and
vaccination, when only 27% of the planned study population was
enrolled. So, this adverse safety signal seen in STEP was not sub-
stantiated in Phambili. However, there were more HIV infections in
the vaccinated group than the placebo group, as discussed below,
suggesting the lack of efﬁcacy of this vaccine candidate.4.3.4.2. Immunogenicity. Immunogenicity was assessed primarily
at the point four weeks after the 2nd injection (for those who
received more than one). Most vaccinees developed gamma-
interferon-secreting T cells against Clade B peptides and more
than three quarters against Clade C peptides. Table 3 in the Gray
et al. (2011) [11] publication outlines these data. Highest frequency
of responses was to the clade B Gag antigen with 89% of Ad5-
seronegatives and 77% of Ad5-seropositives responding. Substan-
tial proportions responded to the other two clade B antigens as well
and tomore than one antigen, withmore than half responding to all
three clade B antigens. In the case of clade C antigens, the highest
frequency of responses was seen to the Pol antigen, with 83% of
Ad5-seronegatives and 67% of Ad5-seropositives responding. More
than half of vaccinees responded to at least two of the three clade C
antigens. Ad5-seronegatives had consistently higher response rates
than Ad5-seropositives, reaching statistical signiﬁcance for some
antigens or for each clade overall. Magnitudes of responses were
not reported in the publication. Given the relatively high frequency
of responses to Clade C antigens by vaccination with the Clade B
vaccine, the rationale to press forward appears sound.4.3.4.3. Efﬁcacy. Although the study was halted early, there were
infections due to risk behavior, which occurred on study, as ex-
pected in an efﬁcacy study despite risk reduction counseling. As
mentioned above, a MITT analysis was performed. Overall, 34 in-
fections occurred in vaccinated subjects and 28 in placebo-
recipients. In women, 22 vaccinees and 20 placebo-recipients
became infected. In men, infections occurred in 12 vaccinees and
eight placebo-recipients. The hazard ratio for infections in women
to men was 1.25 (0.76e2.05 95% CI). Time to infection was also
analyzed. The incidence rate for vaccinees vs. placebo-recipients
was 4.54 vs. 3.70 per 100 person years. Incidence rates were highin women in both groups, 6.79 in women in the vaccinated group
and 5.86 in women in the placebo group.
Predictors of infection identiﬁed in a multivariate Cox propor-
tional hazard model analysis were gender, age, seropositivity to
herpes simplex type 2 (HSV2) and the interaction between gender
and HSV2 (increased risk in men, but not women). In fact, when the
analysis was restricted to women, no predictors of infection were
noted. Parameters that did not signiﬁcantly predict infection were
baseline serostatus or titer to Ad5 (using <18 or >200), number of
inoculations received, or behavioral risk factors. Further, age and
baseline titer to Ad5 did not differ by gender among those who
became infected on study. In men, neither baseline Ad5 titer nor
circumcision status had signiﬁcant association with HIV infection.
Viral load setpoint, as an average of plasma RNA levels at about
two months and about three months post-infection, were obtained
for 61 of those infected on study. There was no difference in dis-
tribution of viral load setpoint between study arms, stratiﬁed by
gender. Women tended to have lower viral load setpoints than
men, but this difference was not signiﬁcant (p¼ 0.15). Also, women
whowere vaccinated tended to have lower viral load setpoints than
women who received placebo, but this difference was also not
signiﬁcant (p ¼ 0.16). Participants who had baseline Ad5 titers <18
(Ad5 seronegative) tended to have higher viral load setpoints than
those who had titers >18 (Ad5 seropositive), but again, this was not
signiﬁcant (p ¼ 0.12).
The co-primary endpoints, with statistical adjustment
(p ¼ 0.39), were not signiﬁcantly different between study groups.
Therefore, the vaccine candidate was not demonstrated to have
efﬁcacy.
After long-term (42 months) follow-up, 63 (35 women, 28 men)
vaccinees and 37 (26 women and 11 men) placebo-recipients had
become infected through risk behavior. Figure 2 in the Gray et al.
(2014) [12] publication shows how the KaplaneMeier curves
appear to diverge after time on study, with infections accruing
more rapidly among vaccinees. Whether this is the effect of dif-
ferential drop-out after unblinding (7.7% annualized rate for vac-
cinees and 8.8% annualized rate for placebo-recipients) or some
other confounder is not clear, although analyses were performed
suggesting this was not an artifact of differential drop-out rates in
the two study arms.
4.3.4.4. Lessons learned relevant to regulatory evaluation. As with
all trials, many lessons are learned operationally and in terms of
study design, with regards to epidemiology in the study population,
about social harms and many other facets. Phambili was no
different in this regard.
One scientiﬁc lesson learned from the combination of the STEP
study and Phambili was that a vaccine candidate that solely elicits T
cells is unlikely to prevent HIV acquisition and may not impact
post-infection control of viral load predicted by animal models. The
Merck Ad5-vectored HIV vaccine candidate, expressing clade B Gag,
Pol, and Nef, elicited strong T cell responses in a majority of those
vaccinated, even if individuals were Ad5 seropositive (i.e., had pre-
existing anti-vector immunity). However, this candidate vaccine
failed to demonstrate efﬁcacy in two separate studies separated by
geography, behavioral risk factors for infection, incidence rates,
genders at greatest risk of infection and other relevant factors. As a
consequence, subsequent vaccine development by the ﬁeld will
primarily be aimed at eliciting a combination of antibodies and T
cells. It is still felt, in the scientiﬁc community, that T cells are
essential to a successful HIV/AIDS vaccine, if for no other reason
than CD4þ T cells are important for antibody elicitation and func-
tion. In fact, it is likely that CD8þ T cells will also be important, but
not sufﬁcient, in a successful vaccine. Thus, as regulators review
CTAs, the proposed immunological mode or mechanism of action of
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to them and evidence provided for immune responses that may
include, but not be limited to, cellular immunity.
One surprising lesson learned from the more recently published
data [12], is that there may be value to not unblind a efﬁcacy study
that has had enrollment and vaccinations halted due to the futility
of the study to demonstrate efﬁcacy, but which continues in follow-
up for safety, including acquisition of HIV infections. By having
unblinded the Phambili studywhen it was halted, it is impossible to
know whether there has been bias introduced into the rate of
acquisition of HIV infections between individuals who know they
received vaccine and those who know they received placebo. There
may even be differential retention between the study groups
because of participants' perception, which may have confounded
themore recent results. Statistical analyses have been performed to
illuminate these potential problems, but it is impossible to know,
because the study was unblinded when enrollment and vaccina-
tions were halted. Unfortunately, this lessonwas learned a little too
late for the HVTN 505 study, which is described below. For future
efﬁcacy studies, due consideration should be given to balancing the
ethics and the right of participants to know in which study arm
they were enrolled against the scientiﬁc and societal value of
continued follow-up in the study in a blinded manner, when a
study is halted early for futility. This is especially the case when
there appears to be a trend towards enhanced acquisition in the
vaccinated arme a safety issue that warrants follow-up and further
scientiﬁc study and analysis in order to determine how to prevent
such safety issues in future efﬁcacy trials with related, or even
unrelated, vaccine candidates. Understanding the mechanism of
action of enhancement, if it occurs, is as important as under-
standing correlates of protection for a successful vaccine. But
ethical considerations will take precedence, as they always should.
4.3.5. RV144
Originally conceived and funded by the U.S. Military HIV
Research Program (USMHRP) and the Ministry of Public Health of
Thailand and ultimately also funded by the Division of AIDS at the
U.S. NIH, the RV144 study was conducted in Thailand. RV144
enrolled from a general population of healthy adults aged 18e30 at
primarily heterosexual risk but including MSM, commercial sex
workers (CSW) and IDU/PWID based on self-reported risk behav-
iors. This study combined the bivalent B/E gp120 vaccine used in
the VAX003 study from Global Solutions for Infection Diseases
(GSID, http://www.gsid.org/, accessed 8/19/2013, USA), who were
granted rights to the product from VaxGen, with an ALVAC vector
prime in a regimen that delivered ALVAC at all four doses and gp120
at the ﬁnal two doses, at 0, 4, 12, and 24 weeks. The ALVAC vector,
vCP1521, was based on the ALVAC from Virogenetics. It expressed
Gag and Pro from clade B (LAI strain) and gp120 from clade CRF_01
(A/E) strain 92Th023, linked to the transmembrane anchoring
domain of gp41 (LAI strain) and was made by sanoﬁ pasteur. This
study was conducted as a complex partnership of multi-national
public and private interests.
Participants were randomized 1:1 vaccine regimen vs. placebo.
The study enrolled 16,402 participants. Originally, the primary
endpoint was the acquisition of HIV infection, but after controversy
was raised in the scientiﬁc community by the conduct of the study,
a co-primary endpoint of viral load was added. The viral load
endpoint was an average of three measures taken within six weeks
of serodiagnosis. The immunogenicity analyses will be further
described in the sections below on immunogenicity and on the
correlates analysis.
Although it may have been conceived as such originally, this
Phase 3 study was not designed to support licensure as a sole trial.
The sample size selected in the target population studied gave onlysufﬁcient power to assess efﬁcacy with a lower bound of the con-
ﬁdence interval to exceed zero, and not 30%, as had been recom-
mended to the U.S. Food and Drug Administration (FDA), who
reviewed and approved the study, by their committee of external
advisors. So, while the sample size was quite large, the study still
risked being underpowered to provide compelling evidence of ef-
ﬁcacy if the point estimate of efﬁcacy was below 50%, as it turned
out to be. Nonetheless, the study served as a test-of-concept or pilot
efﬁcacy study. The data from this study could be considered in
conjugation with another trial of the same or related regimen to
support licensure if convincing and concordant results were ob-
tained, but such a study has not been completed or conducted at
this time. Plans to do so are described in the companion review.
The statistical analyses of the primary endpoint warrant some
discussion, because some of the controversy that arose over the
results of the study was based on the difference in achieving sta-
tistical “signiﬁcance” between the per-protocol and the MITT ana-
lyses. A Cox proportional-hazards method was used. The planned
per-protocol analysis was to include all subjects who received
each of their study treatments within the required time-window,
acquired HIV infection after completion of the entire series, and
were not excluded for other reasons. The ITT analysis included all
subjects randomized to the study. The MITT analysis included all
randomized subjects who received their ﬁrst inoculation and who
were not subsequently determined to be in the window period of
HIV infection (i.e., screen seronegative at baseline, so qualiﬁed for
the study, but later were found to be HIV plasma RNA positive at
ﬁrst inoculation).
A futility analysis was also conducted at planned interim ana-
lyses by an independent DSMB, which met every six to 12 months
(8 times during the study). The futility statistic would have led to
halting the study had the conditional power to detect a difference
in VE between groups fell to less than 10%. Reported p-values were
two-tailed, considered signiﬁcant at the 0.05 level and were not
adjusted for multiple testing.
Controversy over the design and conduct of this study began
after the study was open and enrolling subjects. There were ob-
jections within the scientiﬁc community that the candidate
regimen was not sufﬁciently potent to warrant the expense of
conducting such a large efﬁcacy study, particularly one that would
not in itself support licensure. At that point in time, T cell vaccines
were thought bymany scientists to be the best hope, because broad
neutralizing antibodies were yet to be attained by any candidate or
regimen. Since this regimen did not elicit potent or frequent T cell
responses, several scientists objected to moving forward with the
regimen. As will be noted among the lessons learned, without a
predictive animal model, despite what may be the prevailing sci-
entiﬁc opinion, it is impossible to know what vaccine candidates or
regimens will elicit protective efﬁcacy against HIV infection and
AIDS without conducting an efﬁcacy trial in humans. While some
scientists may have the hubris to believe they know what will or
will notworkwithout having done the experiment, regulatorsmust
remain agnostic. Human efﬁcacy trials must be conducted in order
to know if a candidate HIV/AIDS vaccine will have efﬁcacy.
Although at the time, T cell vaccines were favored, as subsequently
learned from the failure to see efﬁcacy in the STEP and Phambili
studies, this favored hypothesis has proven faulty. While many in
the HIV/AIDS vaccine ﬁeld did not believe that efﬁcacy would be
demonstrated in this study, in fact, it is the only clinical trial so far
that has demonstrated any efﬁcacy, albeit quite modest. As a
consequence of these objections raised after the study was already
enrolling subjects, the primary endpoint was modiﬁed to include a
co-primary endpoint of viral load and CD4 counts among those
who would become infected on study due to their risk behavior.
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was discordance in the statistical signiﬁcance for VE based on the
per-protocol analysis vs. the MITT analysis. In part, this can be
understood on the basis of imperfect adherence to the complete
vaccination series, which resulted in a loss of nearly 4000 of the
16,000 counted in the per-protocol analysis. Since the study sample
size was selected to rule-out zero as the lower-bound of the
conﬁdence-interval, the loss of nearly 25% of participants from the
sample size analyzed had a signiﬁcant impact on the power of the
per-protocol analysis to achieve signiﬁcance and rule-out zero in
the conﬁdence-interval. In contrast, only those individuals found
subsequently to actually have already been HIV-infected at baseline
(n ¼ 7; i.e., nearly all 16,000 were included in the analysis) were
eliminated in the MITT analysis, giving it substantially more power
to detect differences between incident infections in the study arms.
However, for those unfamiliar with the nuances of clinical trial
statistical analyses, the fact that the various analyses were not
concordant in their statistical signiﬁcance caused many to doubt
the results. These doubters considered the statistically signiﬁcant
results to be a statistical “ﬂuke.” In fact, the reason the data are
analyzed in these various ways (PP, ITT, MITT) is exactly to divine
whether a particular analysis is a ﬂuke or whether the analyses do
gain concordance and thus, enhance conﬁdence in the results. In
addition, the impact of waning immunity on the differential rates of
infection between study arms raised concerns. The number of in-
fections that occurred during the time of peak immunity in the
vaccine arm was insufﬁcient to have power to detect a statistical
difference, although there was a clear difference. But by the time
sufﬁcient events had occurred to have the necessary power, the
rates of infections between the two groups were aligning, because
the impact of the vaccine regimen was waning. However, the
ﬁndings of a correlates analysis, described below, have allayed the
concerns among at least some of these doubters.
Some information in this section and subsequent sub-sections
has been taken from the publication of the efﬁcacy study results
by Rerks-Ngarm et al. [13]. Information has been paraphrased or
sometimes directly quoted. Additional information on the out-
comes of this study in regards to an independent statistical eval-
uation (given the controversy of the analyses of the study) and
behavioral risks, respectively, can be found in the literature, but are
not summarized here [14,15].
4.3.5.1. Safety. Local and systemic reactogenicity seen was mostly
mild tomoderate and occurred at similar frequencies and severities
in both study arms. Most reactions resolved within three days post-
vaccination. The number of deaths and the frequency and severity
of SAEs were also similar between the two study arms. More details
were provided in Supplemental Figure 1 and Supplemental
Tables 1a, 1b, and 1c in the Rerks-Ngarm article (Rerks-Ngarm,
2009 [13]). For example, the rates of AEs and SAEs in the 30-days
post-any-vaccination were respectively, 32.4% and 1.5% in the
vaccine arm and 33.4% and 1.8% in the placebo arm. The majority of
SAEs were injuries and the authors have related publicly that
motorbike accidents are an all-too-common occurrence in
Thailand. Thus, there was no indication of a safety signal related to
the vaccine regimen. More detailed safety data were published
separately [16].
4.3.5.2. Immunogenicity. In reality, as was the subject of objection
to the trial, the vaccine regimen was poorly immunogenic in
regards to T cells, although antibody responses were prevalent.
Nearly all vaccinees developed anti-gp120 and anti-Gag antibodies.
GMT to MN gp120 were 13,207 and to A244 gp120 were 14,588.
Anti-p24 antibodies were of lower frequency with GMTof only 138.
Lymphoproliferation was also measured and was signiﬁcantlyhigher in vaccinees. Only 19.7% of vaccinees developed and main-
tained cellular responses at six months post-last-vaccination as
measured by gamma-interferon ELISpot to either Env or Gag anti-
gen. These analyses were the planned immunogenicity measures in
the protocol. However, after efﬁcacy was seen, a correlates analysis
was planned and executed and will be described below. This trial is
the subject of a recent review [17].
4.3.5.3. Efﬁcacy. The analysis for VE, i.e., prevention of HIV acqui-
sition, was performed in three ways, as already alluded to above.
The per-protocol analysis included all subjects who received the
complete vaccination series within the deﬁned time windows and
who were not excluded for other reasons, including acquisition of
HIV before completion of the vaccination series. The ITT analysis
included all subjects randomized into the study. The MITT analysis
included all randomized subjects who received their ﬁrst vaccina-
tion (at least) and who were not subsequently found to be already
HIV-positive at baseline (positive for HIV RNA in the plasma,
although screened seronegative), i.e., only seven subjects were
excluded from the MITT analysis. Each of these analyses was con-
ducted by a Cox proportional-hazards method.
The ITT analysis included 132 infections e 56 in the vaccine arm
and 76 in the placebo arm. VE was estimated at 26.4% with a 95% CI
of 4 to 47.9%, p ¼ 0.08. The per-protocol analysis included 86
events e 36 in the vaccine arm and 50 in the placebo arm. VE was
estimated at 26.2% with a 95% CI of 13.3 to 51.9%, p ¼ 0.16. Finally,
the MITT analysis included all but seven infections that were pre-
sent at baseline for a total of 125 infections e 51 in the vaccine arm
and 74 in the placebo arm. VE was estimated at 31.2% with a 95% CI
of 1.1e51.2%, p ¼ 0.04, achieving statistical signiﬁcance. Other an-
alyses of the MITT population gave statistically signiﬁcant results,
as follows: Barnard's test (p ¼ 0.04), log-rank test (p ¼ 0.04), Wil-
coxon test (p ¼ 0.03), modiﬁcation of time to seroconversion
endpoint (p ¼ 0.04), exclusion of hospital-diagnosed infection
(p ¼ 0.05), and analysis of interval-censored data (p ¼ 0.04).
Subjects' viral loads were assessed at time of diagnosis, three
weeks, and six weeks subsequently, and averaged. Mean viral load
and CD4 counts in those who became infected on study did not
differ between groups. Mean viral loads were 4.36 log10 copies/mcL
in the vaccine arm and 4.21 log10 copies/mcL in the placebo arm in
the ITT population (p ¼ 0.09), 4.24 log10 copies/mcL in the vaccine
arm and 4.19 log10 copies/mcL in the placebo arm in the per-
protocol population (p ¼ 0.47), and 4.30 log10 copies/mcL in the
vaccine arm and 4.20 log10 copies/mcL in the placebo arm in the
MITT population (p ¼ 0.24). Likewise, mean CD4 counts between
the vaccine and placebo arms, respectively, were 541 cells/mcL and
568 cells/mcL in the ITT population (p ¼ 0.47), 572 cells/mcL and
532 cells/mcL in the per-protocol population (p ¼ 0.72), and
555 cells/mcL and 568 cells/mcL in the MITT population (p ¼ 0.76).
The KaplaneMeier curves showing accumulation of HIV acqui-
sition endpoints over time on the study, published in Figure 2 in the
Rerks-Ngarm article, are instructive. They show that the rates of
infections in the two study arms were similar before completion of
the full vaccination series, but in the six months to year following
complete vaccination, the arms diverge. In the MITT analysis that
included infections occurring before the vaccine series was com-
plete, divergence begins to be seen even earlier (after two or three
vaccinations). Subsequently, however, the study arms become
parallel in their slope as new infections accumulate in both study
arms at approximately the same rate. These ﬁgures lead one to
surmise that the efﬁcacy that was seen waned, as immune re-
sponses likely waned. Although the ﬁnal statistically signiﬁcant
result (MITT) was 31.2% efﬁcacy seen at three years post-last-
vaccination, at six and 12 months post-last-vaccination, the point
estimate of efﬁcacy was closer to 60%. It is noted however, there
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difference between the study arms.
4.3.5.4. Correlates analysis. Subsequent to the completion of the
RV144 study, a correlates analysis was planned and implemented. A
large number of analyses were performed, but six were prospec-
tively identiﬁed as primary analyses. One of these parameters, anti-
V1V2 IgG antibodies, correlated inversely with risk of HIV acqui-
sition in vaccinees, whereas another, IgA antibodies, correlated
directly with risk of HIV acquisition among vaccinees. Identiﬁed
correlates of risk (those with inverse correlations) could be evalu-
ated in future efﬁcacy trials as potential correlates of protection. It
should be borne in mind that a correlate of protection for one
vaccine candidate or regimen may not be the same for a different
candidate or regimen that is expected to have a different mecha-
nism or mode of action. This immune correlates analysis is pub-
lished, as is a review of the lessons learned [17,18].
4.3.5.5. Lessons learned relevant to regulatory evaluation. As stated,
despite wide-spread scientiﬁc controversy about the likelihood
that this candidate regimen would demonstrate efﬁcacy, this was
the only efﬁcacy study performed so far in which modest efﬁcacy
was seen. This fact emphasizes that we must remain humble and
agnostic about outcomes of scientiﬁc studies until the well-
controlled, well-designed studies are performed and the results
become known. Regulators should take note of this uncertainty and
while it is requisite to provide scientiﬁc justiﬁcation to support the
conduct of any clinical trial, the lack of a predictive animal model or
natural survivors in the HIV/AIDS ﬁeld precludes reliance on such
data to justify going forward with any particular vaccine candidate
or regimen. Immunogenicity data from human clinical trials and a
plausible proposed mechanism of action are necessary to proceed
to efﬁcacy studies, but which candidates or regimens should
advance and which do not warrant the effort, resources, time and
expense remains controversial within the HIV/AIDS scientiﬁc
community. In fact, to date, the most potent of candidate regimens
e arguably the Merck Ad5 vector (described above) and the VRC's
DNA prime-Ad5 boost (described below) e have failed to achieve
efﬁcacy in prevention of acquisition or in control of viral load in
those who become infected through their own risk behavior after
vaccination. In fact, the Merck vector (solely eliciting T cells) may
have been associated with enhanced risk of HIV infection, while the
less potent candidate regimen studied in RV144, did achieve some
modest degree of efﬁcacy in terms of prevention of HIV acquisition.
Clearly, we still have a lot to learn about what types and amounts of
immune responses are needed for efﬁcacy.
One major consideration that was taken by the Government of
Thailand was the impact of efﬁcacy outcomes in VAX003 on the
conduct of RV144, once the outcome of VAX004 became known,
since one component of the regimen in RV144 was the vaccine
tested in VAX003. A consultation was held by the WHO-UNAIDS
HIV Vaccine Initiative to advise the Ministry of Public Health of
Thailand in this regard. Consideration was given to different po-
tential outcomes, including high efﬁcacy, modest efﬁcacy, and low
or no efﬁcacy. (At that time, the potential for enhancement had not
been seen and was not considered.) RV144 showed that even if a
component of a regimen is insufﬁcient on its own to elicit protec-
tive efﬁcacy that does not mean a priori that it cannot contribute as
an element in a successful regimen. While it has not been deﬁni-
tively established that the efﬁcacy seen in RV144 was not elicited
solely by the ALVAC vector, because it was not tested alone, the
correlates analysis suggests strongly that there was contribution
from the protein boost. Thus, the combination of the prime-boost
regimen enhanced whatever immune responses resulted in pro-
tective efﬁcacy, which were not elicited by the protein alone.Whether this was a qualitative or quantitative difference or both is
as yet unknown.
A lesson learned relevant to regulatory evaluation is the
consideration of which analysis is the most relevant for vaccine
efﬁcacy. Generally, one would consider that the per-protocol
analysis, which is selected to analyze the best-case-scenario for a
vaccine, would be the most relevant. Intent-to-treat analyses are
often relevant in the case of drug trials because of differential
adherence to a drug regimen. Vaccine regimens, in contrast, are
short (generally three to ﬁve doses, but given over months) and
thus, considerably easier for adherence. Also, they are given by
clinicians rather than the trial subject themselves, so adherence can
be deﬁnitively established. Given the window period for HIV
infection and the months between the ﬁrst dose of the vaccine and
the last, arguably the most relevant analysis is the modiﬁed-intent-
to-treat analysis. The MITT includes every subject who received at
least their ﬁrst inoculation (vaccine or placebo) and who subse-
quently is shown to be HIV-uninfected at baseline (some in-
dividuals who are seronegative at baseline may actually be infected
and in the “windowperiod”, and identiﬁed later as being infected at
baseline). Although the MITT population does not represent the
“best-case-scenario” in which the full vaccination series is given
and time elapsed to permit an adequate immune response to
develop, the MITT analysis reﬂects a real-world scenario of pro-
tecting uninfected individuals by vaccination, since they may
become infected anytime during or after the course of the vacci-
nation series. In the case of RV144, only the MITT analysis achieved
statistical signiﬁcance. In part, the per-protocol analysis did not
achieve signiﬁcance, because power was lost by virtue of problems
in adherence to the full vaccination series (mostly due to “falling
out” and missing the prospectively deﬁned window of opportunity
for vaccination even though the vaccinations were given, just not
on time). So fewer individuals (12,542 out of the 16,402) were
included in the per-protocol analysis e in contrast to the MITT
analysis, which included 16,395 of the 16,402 enrolled. Only 86
infections were included in the per-protocol analysis, while 125
infections were included in the MITT, enhancing its power to detect
differences. Clarity on the analysis plan should be provided by the
applicant for regulatory evaluation. The statistical analysis plan
should be provided prospectively for regulatory evaluation. Regu-
lators should play particular heed to the MITT analysis in vaccine
studies, because of the timing of vaccine dosing and exposure to the
disease organism. Ideally, all analyses will be concordant,
enhancing conﬁdence in the results. When discordant results are
seen, attention should be paid to which analysis was signiﬁcant and
why the analyses may have been discordant.
Furthermore, regulators should take note of the issues that
would impact credibility of the trial results and seek clarity in how
a study sponsor plans to power and analyze an efﬁcacy study, to
avoid a loss of conﬁdence in the study outcomes. Credibility of the
results is essential to regulatory decision-making. It is for this
reason, among others, that FDA's external advisors recommended
licensure decisions only be made on an efﬁcacy study in which the
lower bound of the conﬁdence-interval exceeded zero by a good
margin (e.g., 25e30%). This requires either a point estimate of ef-
ﬁcacy be reasonably high (50%) or the trial be designed to have
sufﬁcient precision to have a tight conﬁdence-interval around the
point estimate or both.
The issue of waning immunity is another issue on which regu-
lators should be concerned when reviewing CTAs. The study design
should address this andmight do so in multiple different ways. One
option might be to continue to boost subjects every six months or
yearly during the study, in a multi-year follow-up study. Of course,
this approach would have implications for how the vaccine would
need to be used, once licensed. Another optionwould be to conduct
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in RV144. In that manner, more events would occur in a shorter
time-frame potentially obviating the need for a three-year follow-
up. However, such a population might represent a more stringent
challenge for the vaccine regimen and may not be generalizable to
the populations in which any particular country might wish to
deploy a successful vaccine. As a ﬁnal option, the sample size of the
study might be increased in order to have sufﬁcient events in a
shorter time-frame of follow-up, but this raises several logistical
and operational challenges (and potentially ethical ones as well, as
more subjects could be put at risk before the vaccine is revealed as
beneﬁcial or not) and may not be feasible. Furthermore, the time to
enroll such a large sample would likely take multiple years itself,
further complicating the study and the analyses, as bias could be
introduced over time due to a changing landscape in both
standard-of-prevention and standard-of-care (including
treatment-as-prevention and effects on viral load as a study
endpoint).
The correlates analysis from RV144 is instructive in many ways.
First, the analysis would have been greatly facilitated had more of
the “right” samples been taken. Samples taken in the right fre-
quency and time-frame post-vaccination and post-infection would
have greatly enhanced the ability to discern meaningful differences
between vaccinees who became infected and those who may have
been protected. The “right” samples in terms of serum, plasma, or
cells, in terms of blood or mucosal specimens and so forth, must
also be considered. All of this and the potential to enhance the
science and knowledge gained from a hopefully successful efﬁcacy
study needs to be weighed against the logistics and operational
costs (resources, time, and expense) of additional subject visits;
objectionable and potentially more risky, more invasive sampling
procedures; additional processing and storage of samples;
increased complexity of study design and analysis; potentially
increased difﬁculty in recruitment and retention; and the impos-
sibility of knowing a priori who will be the ones that become
infected and who will be protected (precluding focus on obtaining
more specimens from those).
More lessons have been learned from the correlates analysis.
The importance of prospectively prioritizing the analyses cannot be
minimized when considering reducing the power to deﬁne
meaningful differences. Recognition should be taken and plans
made accordingly to account for new techniques that will become
available, standardized, validated and meaningful between the
time the study is planned and initiated and when the analyses (if
batched and not performed “real-time”) are performed at the end
of the study. Also relevant to regulatory considerations is the dif-
ference between a pilot efﬁcacy study in which correlates of pro-
tection or correlates of risk for infection, as identiﬁed in RV144, are
hypothesis-generating, vs. the hypothesis-testing of correlates of
protection that ideally would be accomplished in a pivotal efﬁcacy
study. Given the state of the HIV/AIDS vaccine ﬁeld however, even
pivotal efﬁcacy studies may be performed with correlates analyses
that are hypothesis-generating, as correlates of protection have yet
to be identiﬁed and validated. Further, it is feasible for vaccines
with differing mechanisms of actions (types and amounts of
different kinds of immune responses, such as antibodies or cellular
or systemic or mucosal, different functions of antibodies, different
functions of cells, etc.) that there could be different correlates of
protection. So, even if the correlates of risk identiﬁed in RV144 are
shown to be correlates of protection in future efﬁcacy studies of
poxvirus primes with protein boosts, another candidate regimen
(e.g., DNA-prime, poxvirus-boost) may have different correlates of
protection. To understand this better, it might be helpful to think
about the differences between the oral poliovirus or Sabin vaccine
and the inactivated poliovirus or Salk vaccine. While both elicitsystemic antibody responses that are sero-protective in the indi-
vidual vaccinee, it is believed that some of the mode of action of the
Sabin vaccine is via establishing mucosal immunity in the gut,
which is the portal of entry for polioviruses. Limiting infection in
the gut not only protects the vaccinated individual but also reduces
the virus shed into the environment, interrupting transmission. The
Salk vaccine is not thought to have this transmission-blocking
effect.
4.3.6. HVTN 505
The HVTN 505 study was originally planned as PAVE 100, a
multi-network, multi-national study of the Vaccine Research Cen-
ter's (VRC, NIAID, USA) regimen using the following combination of
vaccines in a prime-boost approach. The priming doses, a series of
three given one month apart and delivered by Biojector® 2000
needle-less injection system, consist of a mixture of six DNA plas-
mids expressing Gag, Pol, Nef, and Env from clade B, and two
additional Env proteins from clade A and C. The dose of this mixture
given was 4 mg total at each priming inoculation time. The single
boost dose given at month six, after a four-month rest from the
priming series, consists of a mixture of four Ad5-vectors expressing
Env from clades A, B, and C and a Gag-Pol fusion protein from clade
B. The dose of Ad5 vector given was 1  1010 particle units (PU)
total.
The PAVE 100 study was due to open for enrollment the week
after the STEP study results were announced and that study was
halted for futility. Because the STEP study used an Ad5 vector and it
appeared that there may have been enhanced risk of acquisition of
HIV infection in those vaccinated who were Ad5-seropositive at
baseline, controversy was raised whether there was equipoise to
conduct PAVE 100. PAVE 100 would have enrolled, among others,
Ad5-seropositive individuals and menwhowere uncircumcised. As
a consequence of this controversy and turn of events, PAVE 100 was
abandoned, additional supportive animal data were gathered to
assess the risk of enhanced acquisition, as well as protective efﬁ-
cacy, with the animal model analogs of the VRC regimen, and the
clinical study was redesigned.
HVTN 505 was, consequently, conducted solely in the U.S. in
circumcised men who were Ad5-seronegative MSM or trans-
gender (male-to-female). It was designed as a test-of-concept
Phase 2b study. It was originally designed to enroll 1350 partici-
pants and focus on a viral load endpoint as primary efﬁcacy indi-
cator, but with additional supportive animal data, the study was
increased to enroll 2200 participants with a co-primary endpoint of
acquisition of HIV infection and viral load in those who became
infected on study from risk behavior. The results of PrEP studies
were announced while HVTN 505 was enrolling. So, the ﬁnal
accrual goal was raised to 2,500, to account for potentially
decreased acquisition endpoints from PrEP use. PrEP use was
permitted on study, because PrEP was viewed as likely to become
standard-of-prevention in the U.S. and could not ethically be
discouraged. In the end, 2504 volunteers were enrolled before an
interim analysis for efﬁcacy determined that the study should halt
vaccinations due to the futility to be able to demonstrate either co-
primary endpoint. The study was unblinded as soon as possible
thereafter so that participants would know which study treatment
they received. Counseling on risk reduction continued to be pro-
vided and the study was continued in follow-up for safety,
including acquisition of HIV infection.
Information in this section is quoted directly or paraphrased
from Hammer et al. [19].
4.3.6.1. Safety. In general, DNA plasmid vaccines have been found
to be quite safe and well-tolerated. In particular, the VRC's six-
plasmid candidate prime vaccine, resulted predominately in local
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has been noted infrequently in studies of the VRC's DNA prime. One
point that bears remark is that the Biojector®, when used to deliver
the DNA plasmid vaccine, sometimes results in a small lesion at the
site of injection. These lesions frequently go unnoticed by the
subject, resolve, and have not resulted in any adverse consequences
to date. The Ad5 boost results in more systemic reactions than the
DNA prime, with headache, malaise, and myalgia being the most
common. In both cases (DNA prime, Ad5 boost), reactions were
self-limiting and resolved generally within 24e48 h. In HVTN 505,
vaccinees had signiﬁcantly higher rates of reactogenicity than did
placebo-recipients. Most reactions were mild to moderate. Non-
fatal, non-reactogenicity adverse experiences were balanced be-
tween vaccinees and placebo-recipients. Only one severe AE was
judged to be related to vaccination, a severe viral syndrome (it
should be noted that the Ad5 vector is not replication-competent in
humans or in cells other than those that have been engineered to
complement the defects in both the Ad5 E1 and E4 ORF6 genes). Six
subjects, placebo-recipients, died on the study.4.3.6.2. Immunogenicity. The VRC regimen elicits robust antibody
and T cell responses. In HVTN 505, 61.5% of vaccinees developed
vaccine-speciﬁc CD4 T cells and 64.1% of vaccinees developed
vaccine-speciﬁc CD8 T cells, as determined by Intracellular Cyto-
kine Staining (ICS). Predominant targets of these T cells were Gag
(48.7%) and Env (38.5%) for CD4 T cells (responses on order of 0.1%
of total T cells) and Env (56.4%) for CD8 T cells (0.2%). 100% of
vaccinees developed IgG antibodies to HIV Env of the vaccine
strains (A, B, and C clades), to a Group M consensus Env (gp140, a
truncated gp160), and to the gp41 component of Env. 48% of vac-
cinees developed IgG antibodies to the gp120 component of Env.
IgG responses to V1V2 domains of Env were low (18% to the antigen
used in the correlates analysis of RV144 and 20% to a VRC Clade A
strain matched to the vaccine). Serum IgA responses were 43%.
Neutralizing antibodies were also low (2.5e27.5%) and present only
to Tier 1 virus strains (the easier-to-neutralize viruses, see the
companion review for more information about this categorization
scheme).4.3.6.3. Efﬁcacy. The HVTN 505 study was halted early at the
recommendation of the DSMB, in April 2013. The study was fully
enrolled and most participants were fully vaccinated. The primary
endpoint was infections occurring betweenweek 28 on study (after
the entire vaccination series) and month 24. At the time of the
DSMB review, there were 27 vaccinees and 21 placebo-recipients
who had become HIV infected in this period of time. Vaccine efﬁ-
cacy was estimated at 25% (95% CI, 121.2 to 29.3, p ¼ 0.44).
Overall, there were 41 vaccinees and 31 placebo-recipients who
had become HIV infected on study inclusive of the primary
endpoint window and all other timepoints on study (p ¼ 0.028).
Thus, the DSMB recommended that efﬁcacy could not be demon-
strated and the study should be halted for futility. Subsequent data
up until September 2013, as presented at the NIH Mini-Summit,
discussed in Section 4.3.7 below, revealed additional infections
that evened out the rates of infection between the two arms of the
study. There were 43 vaccinees and 39 placebo-recipients infected
during the study by the time of that analysis (presented at theMini-
Summit).
Viral setpoints were, on average, 4.46 and 4.47 log10 HIV RNA
copies/mL, respectively, in the vaccine and placebo groups, in in-
dividuals who had become infected on study. Thus, the vaccine
regimen lacked both the ability to prevent acquisition of HIV
infection or to modulate viral load in vaccinees who became
infected during the study through their risk behavior.4.3.6.4. Lessons learned relevant to regulatory evaluation. In the
end, many lessons were learned from the conduct of HVTN 505.
One lesson is that one must be prepared to adjust the study design
of an on-going study when the results of other studies become
available, e.g., when PrEP became more widely used in the U.S.,
where HVTN 505 was being conducted. Although the rate of PrEP
uptake was not high, there needed to be a means to assess and
monitor the uptake and adjust the study so that it did not become
underpowered to assess efﬁcacy as a consequence of other pre-
vention strategies being used in the study communities. In fact,
PrEP uptake during the study varied by location of site from as little
as about 2% to as much as 12%. This likely reﬂects differences in
trends among various HIV-affected communities in the U.S. Regu-
lators need to be aware of the prevention strategies that may be
considered to be standard-of-prevention in their country, com-
munities and/or study populations in order to assure that trial
sponsors are conducting their studies appropriately. Further, reg-
ulators need to consider the review and evaluation of study pro-
tocol amendments when new prevention strategies begin to be
implemented. While it is generally considered to be inappropriate
to amend primary endpoints of efﬁcacy studies that are on-going,
other events that have occurred locally or globally may require
such amendments be considered in order to maintain appropriate
ethical standards while assuring that a study continues to have the
possibility to meet its stated aims.
4.3.7. NIH Mini-Summit on Adenovirus-vectored HIV vaccines
Given the results of STEP, Phambili, and HVTN 505, a Mini-
Summit was held on 19 September 2013, hosted by NIH, who had
funded these three studies. The Mini-Summit brought together
experts to address certain questions and uncertainties arising from
the outcomes of these studies. Although it was obvious from the
study results that the tested Ad5-based HIV vaccines were not
efﬁcacious, it is unclear as to what impact the results from these
vaccines have on candidates based on alternative adenovirus-based
vectors. Both alternative (lower seroprevalent) human adenovi-
ruses, as well as other species' adenoviruses, are being explored in
preclinical and early clinical studies. While they are all members of
a particular family of viruses (adenoviruses), meaning they are
genetically related and share many commonalities, their biologies
can be very different, including receptor usage, organ and species
tropism, epidemiology, clinical syndromes they cause, etc. In
addition, while the STEP study had a safety signal (enhanced
acquisition), which was observed in a subset of vaccinated in-
dividuals, this safety signal was not clearly seen in Phambili (which
was halted before full enrollment) or HVTN 505 studies.
Themajorconclusionof theMini-Summitwas that theMerckAd5
HIV vaccine candidate, which was based on Ad5 and did not express
Env, was associated with enhanced risk of HIV acquisition, but that
everything else was uncertain. The VRC Ad5 HIV vaccine candidate
was not associated with enhanced risk of HIV acquisition. The VRC
Ad5vaccine candidate differs in signiﬁcantways from theMerckAd5
HIV vaccine candidate, including the expression of Env, which elicits
antibody responses as well as T cell responses. The differences be-
tween the candidates are outlined in Section 4.3.6 above. Despite the
uncertainties, it was concluded that there is sufﬁcient scientiﬁc
justiﬁcation to continue to investigate alternative adenovirus sero-
types and other species' adenoviruses as vectors of HIV vaccine
candidates, including in heterologous prime-boost combinations.
Exploration of the biological mechanism of enhancement of infec-
tion, as well as a better understanding of the biology of the vectors,
must bea scientiﬁc priority, to ensure safedevelopmentof futureHIV
vaccine candidates,whether they are based on adenovirus vectors or
other vectors. Understanding the mucosal immune response to
vaccines andvectors, particularlyactivationof Tcells andhomingof T
Table 1
Summary of lessons learned from completed HIV/AIDS vaccine efﬁcacy trials relevant to regulatory evaluation of clinical trial applications for vaccines in development.
Trial Lessons learned relevant to regulatory evaluation
VAX004  Need for clarity in statistical analysis plan to support clinical claims
 Sub-group analyses
 Hypothesis-generating vs. hypothesis-testing
 Statistical adjustments for multiplicity
VAX003  Studies in marginalized populations can be feasibly and successfully conducted
 Needs political will & commitment on part of investigators, regulators, governments, participants
Step  T cell immunity alone is unlikely to be sufﬁcient to prevent HIV infection or modulate disease in vaccinees who become infected
through risk behavior
 Regulators should expect applicant to explain intended mode-of-action of vaccine & it should include some element of
antibody-mediated immunity (T cell immunity may be necessary but insufﬁcient)
 Despite scientiﬁc hypotheses, it remains unknown what type(s) or levels of immunity are required for a successful HIV/AIDS vaccine,
so applicant's justiﬁcation should be reviewed with an agnostic perspective as to strength of justiﬁcation and plausibility
 Vaccine-elicited immune responses may paradoxically enhance risk of HIV infection instead of protecting against it
 This potential risk should be described in informed consent process & documents
 Need for clarity in statistical analysis plan:
 One-tailed vs. two-tailed (vaccine could be worse or better than control) p-values
 Associations of efﬁcacy endpoints & sub-group risk prognostic factors
Phambili  T cell immunity alone is unlikely to be sufﬁcient to prevent HIV infection or modulate disease in vaccinees who become infected
through risk behavior
 Balance value of continued blinded safety follow-up in trial halted early vs. ethics of informing participants by unblinding when trial is
halted except for continued safety follow-up
RV144  An HIV/AIDS vaccine can prevent acquisition of HIV infection
 Need for scientiﬁc openness (remain agnostic) when reviewing applicant's proposed hypotheses & mode-of-action
 Only a human efﬁcacy trial that is well-designed, well-controlled, & well-conducted can provide necessary data on whether a
proposed vaccine regimen can protect humans against HIV acquisition
 Need to consider the impact of outcomes of efﬁcacy trials of components or related products to the regimen/vaccine under review or
while the reviewed trial is on-going
 Because a component tested alone or a related product or regimen fails to have efﬁcacy does not necessarily mean that the regimen
being tested will also fail (the sum may be greater than the parts)
 Statistical plan:
 For preventive vaccines, MITT analysis may be most meaningful
 Regulators should receive for review prospectively deﬁned statistical analysis plan & possible interpretations/potential label claims
to be made
 For credibility & regulatory decision-making, agreement should be gained in advance on what would constitute a type
(which endpoint) and amount of efﬁcacy that would be considered to support licensure, including lower bounds of 95%
conﬁdence intervals (e.g., they should exceed what amount in order to provide credible, compelling evidence sufﬁcient
to warrant licensure)
 Multiplicity of immunological endpoints, need for prioritization of statistical analyses to retain credibility in outcomes
 Impact of potential waning immunity on trial design, sample size, length of follow-up
 Prospective plan for collecting “right” specimens to aid correlates analysis
 Regulatory recognition of the distinction between pilot and pivotal efﬁcacy trials in terms of design & statistical power,
hypothesis-generation vs. hypothesis-testing
 Different vaccine regimens/candidates may have different immune correlates of protection determined by their unique mode-of-action
HVTN 505  Studies may need to be adjusted while on-going to account for outcomes in other trials or changes in standards of care &/or prevention
 Need to continue to perform studies meeting international ethical principles, even if practices change while study is on-going
 Such adjustments may include changes to primary endpoint or to other endpoints, study procedures, sample size, etc.
All  HIV/AIDS vaccine efﬁcacy trials are complex, but can be successfully & ethically conducted giving credible results as to a candidate
vaccine's/regimen's efﬁcacy or lack thereof
 Need for evaluating trials with scientiﬁc openness, recognizing uncertainties
 Some HIV/AIDS vaccine candidates can be protective against HIV infections acquired through risky behaviors, but others can paradoxically
enhance risk of HIV infections acquired through risky behaviors
 Type & amount of immune response from HIV/AIDS vaccine candidates needed for efﬁcacy remains unknown, but will likely require at
least some type of antibody-mediated effect
 Clarity on statistical analysis plans is essential
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following exposure to vectors or vaccines is also crucial. The advice
byexperts given to theNIHduring theMini-Summitwill guide future
funding decisions by the NIH and likely, other donors [20].
5. Conclusions
The clinical trials that have been conducted to date have not yet
revealed a highly efﬁcacious HIV/AIDS vaccine candidate or
regimen. However, innumerable lessons have already been learned
from the conduct of these studies and this review highlights those
lessons learned as relevant to the regulatory considerations to be
taken upon review of a CTA. A tabular summary of these is provided
in Table 1. This review along with the companion review should aid
regulators worldwide to focus on the key aspects and scientiﬁcuncertainties that present regulatory hurdles to their decision-
making. However, regulators in individual countries, reviewing a
CTA, should not feel that they are alone in this matter. As will be
discussed in greater detail in the companion review and as was
introduced in this review, advice from various WHO-supported
regulatory fora can and should be sought to aid in dealing with
these scientiﬁc uncertainties when making regulatory decisions.
Among the key lessons learned in the conduct of the six
completed well-designed, well-conducted efﬁcacy studies is that
HIV/AIDS vaccine efﬁcacy studies can be conducted safely and
ethically, with good recruitment and retention, and giving deﬁni-
tive and useful results. Although each of the six completed trials
had some degree of controversy associated with it, these contro-
versies arose as a result of scientiﬁc uncertainty and not for reasons
of misconduct or poor design. Each subsequent study built on
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that those involved with HIV vaccine trials should remain agnostic
and humble in the considerations of the merit of future clinical
trials, including when candidates should advance to efﬁcacy
studies. Despite what may be the most prevailing scientiﬁc theory
at any given moment, efﬁcacy trials should continue and be
designed sufﬁciently to give deﬁnitive results, upon which regu-
latory decisions may be made, when appropriate. It is unlikely that
vaccines that work by simply eliciting a single arm of the immune
system will protect against HIV acquisition or viral load control in
thosewho become infected despite vaccination. Correlates analyses
should be planned prospectively hand-in-hand with efﬁcacy study
trial design and the appropriate specimens, in regards to timing of
collection, handling, and storage, must be taken. Likewise, appro-
priate assay methods need to be used, to facilitate identiﬁcation
and/or characterization of potential immune correlates of protec-
tion. Similarly, appropriate immunological samples may help to
characterize untoward safety signals should they be seen in future
efﬁcacy trials.
This review has shown that statistical plans must be clear in
many regards. Not only should decisions prospectively be made
about which analyses should proceed as hypothesis-testing or only
as hypothesis-generating when primary analyses fail to achieve
signiﬁcance, requiring a hierarchical arrangement of analyses, but
also that clarity is required regarding the relevance of per-protocol,
intent-to-treat, and modiﬁed-intent-to-treat analyses. This is
especially true when they do not all reach the same statistical
signiﬁcance (though trends to signiﬁcance may be concordant with
other signiﬁcant outcomes). The review also conﬁrms that HIV
acquisition must be part of the primary analysis of an HIV/AIDS
vaccine efﬁcacy trial, because it is known that prevention of
acquisition by vaccination is feasible. A communications plan pro-
spectively in place before the results of a study becomes known is
crucial to fair and balanced reporting of results without raising false
hopes or confusion and thus, discord, controversy, or distrust.
Credibility is key to the ability to make regulatory decisions.
We have learned that populations that may have thought to be
impossible to recruit and retain can be studied successfully through
the political will of the researchers, communities, governments,
and countries in which those studies are to take place. It is also
known that the informed consent process must continue to make
potential participants aware that the experimental vaccine(s) they
may or may not receive in a controlled study may not only not
beneﬁt them, but could be harmful to them. Although the hope is
that any vaccine candidate will be of beneﬁt, of course, those
involved should be agnostic until the study is completed and before
there is evidence to know whether the vaccine candidate was
protective, was not protective but not harmful, or was harmful.
Regulators need to continue ensuring trials are planned with
appropriate informed consent processes. Similarly, regulators need
to be cognizant of the status of other prevention modalities and
standard of care and treatment in use in their country and the
communities where potential efﬁcacy trials will take place in order
to ensure that sponsors address these issues in their trial design
and planning.
Achieving the development of a safe, effective, globally-useful
HIV/AIDS vaccine is paramount to the control of the epidemic
and regulators should expect they will need to make decisions inthe face of and despite signiﬁcant scientiﬁc uncertainty. Regulators
in individual countries are not alone in facing their decisions when
reviewing CTAs and should recognize the resources available to
them, particularly from the World Health Organization. It is hoped
that this and the companion review will aid regulators in LMIC feel
more prepared for this challenge.
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